<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79661</article-id><article-id pub-id-type="doi">10.7554/eLife.79661</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Effects of dopamine D2/3 and opioid receptor antagonism on the trade-off between model-based and model-free behaviour in healthy volunteers</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-277366"><name><surname>Mikus</surname><given-names>Nace</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3445-9464</contrib-id><email>nace.mikus@univie.ac.at</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174290"><name><surname>Korb</surname><given-names>Sebastian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3517-3783</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-176024"><name><surname>Massaccesi</surname><given-names>Claudia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0519-6324</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278666"><name><surname>Gausterer</surname><given-names>Christian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4875-5459</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-176026"><name><surname>Graf</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-176027"><name><surname>Willeit</surname><given-names>Matthäus</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278667" deceased="yes"><name><surname>Eisenegger</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="fn1">§</xref><xref ref-type="fn" rid="fn2">‡</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-69245"><name><surname>Lamm</surname><given-names>Claus</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5422-0653</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-100688"><name><surname>Silani</surname><given-names>Giorgia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4284-3618</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-278668"><name><surname>Mathys</surname><given-names>Christoph</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4079-5453</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03prydq77</institution-id><institution>Department of Cognition, Emotion, and Methods in Psychology, Faculty of Psychology, University of Vienna</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01aj84f44</institution-id><institution>Interacting Minds Centre, Aarhus University</institution></institution-wrap><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02nkf1q06</institution-id><institution>Department of Psychology, University of Essex</institution></institution-wrap><addr-line><named-content content-type="city">Colchester</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03prydq77</institution-id><institution>Department of Clinical and Health Psychology, Faculty of Psychology, University of Vienna</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05n3x4p02</institution-id><institution>FDZ‐Forensisches DNA Zentrallabor GmbH, Medical University of Vienna</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05n3x4p02</institution-id><institution>Department of Psychiatry and Psychotherapy, Medical University of Vienna</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02crff812</institution-id><institution>Translational Neuromodeling Unit (TNU), Institute for Biomedical Engineering, University of Zurich and ETH Zurich</institution></institution-wrap><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/004fze387</institution-id><institution>Scuola Internazionale Superiore di Studi Avanzati (SISSA)</institution></institution-wrap><addr-line><named-content content-type="city">Trieste</named-content></addr-line><country>Italy</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kahnt</surname><given-names>Thorsten</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fq5cm18</institution-id><institution>National Institute on Drug Abuse Intramural Research Program</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taffe</surname><given-names>Michael A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0168r3w48</institution-id><institution>University of California, San Diego</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="fn" id="fn1"><label>‡</label><p>Deceased</p></fn><fn fn-type="other" id="fn2"><label>‡</label><p>Deceased on the 27th of February 2017.</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>05</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e79661</elocation-id><history><date date-type="received" iso-8601-date="2022-04-21"><day>21</day><month>04</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-11-22"><day>22</day><month>11</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-03-04"><day>04</day><month>03</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.03.03.482871"/></event></pub-history><permissions><copyright-statement>© 2022, Mikus et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Mikus et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79661-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-79661-figures-v1.pdf"/><abstract><p>Human behaviour requires flexible arbitration between actions we do out of habit and actions that are directed towards a specific goal. Drugs that target opioid and dopamine receptors are notorious for inducing maladaptive habitual drug consumption; yet, how the opioidergic and dopaminergic neurotransmitter systems contribute to the arbitration between habitual and goal-directed behaviour is poorly understood. By combining pharmacological challenges with a well-established decision-making task and a novel computational model, we show that the administration of the dopamine D2/3 receptor antagonist amisulpride led to an increase in goal-directed or ‘model-based’ relative to habitual or ‘model-free’ behaviour, whereas the non-selective opioid receptor antagonist naltrexone had no appreciable effect. The effect of amisulpride on model-based/model-free behaviour did not scale with drug serum levels in the blood. Furthermore, participants with higher amisulpride serum levels showed higher explorative behaviour. These findings highlight the distinct functional contributions of dopamine and opioid receptors to goal-directed and habitual behaviour and support the notion that even small doses of amisulpride promote flexible application of cognitive control.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>reinforcement learning</kwd><kwd>cognitive control</kwd><kwd>decision-making</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001821</institution-id><institution>Vienna Science and Technology Fund</institution></institution-wrap></funding-source><award-id>CS15- 003</award-id><principal-award-recipient><name><surname>Silani</surname><given-names>Giorgia</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001821</institution-id><institution>Vienna Science and Technology Fund</institution></institution-wrap></funding-source><award-id>VRG13-007</award-id><principal-award-recipient><name><surname>Eisenegger</surname><given-names>Christoph</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Blocking D2 dopamine receptors increases goal-directed (“model-based”) control when alternative habitual (&quot;model-free&quot;) actions are available, whereas blocking opioid receptors does not seem to have an effect on the arbitration between the two modes of acting.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Several theories of decision making postulate the existence of two distinct systems that drive our behaviour: a habitual system, which is automatic, reflexive and fast; and a goal-directed system, which is deliberative, reflective and effortful (<xref ref-type="bibr" rid="bib21">Dickinson, 1985</xref>; <xref ref-type="bibr" rid="bib23">Dolan and Dayan, 2013</xref>; <xref ref-type="bibr" rid="bib5">Balleine and O’Doherty, 2010</xref>). This dichotomy of systems has a computational analogue in ‘model-free’ and ‘model-based’ decision-making models (<xref ref-type="bibr" rid="bib23">Dolan and Dayan, 2013</xref>; <xref ref-type="bibr" rid="bib13">Daw et al., 2005</xref>). A model-free agent simply selects actions that have led to rewarding outcomes in the past. This strategy is fast, computationally cheap, but can be inaccurate. A model-based agent uses an internal model of the environment to flexibly plan behavioural responses. This leads to more goal-oriented behaviour but is slower and relies on effortful cognitive control.</p><p>Studies investigating how individuals allocate control between the two systems have shown that model-based control is increased when there is more to gain (<xref ref-type="bibr" rid="bib72">Patzelt et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Kool et al., 2017</xref>), and decreased when cognitive resources are scarce (<xref ref-type="bibr" rid="bib71">Otto et al., 2013b</xref>; <xref ref-type="bibr" rid="bib70">Otto et al., 2013a</xref>). Everyday behaviour can therefore be thought of as constant weighing of costs and benefits of applying model-based over model-free decision-making strategies (<xref ref-type="bibr" rid="bib46">Kool et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Daw et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Kool and Botvinick, 2018</xref>). Failure to exert cognitive control over habitual urges in order to avoid negative outcomes has been suggested to be a hallmark of substance addiction (<xref ref-type="bibr" rid="bib23">Dolan and Dayan, 2013</xref>; <xref ref-type="bibr" rid="bib29">Everitt et al., 2008</xref>). In support of this, studies show that decreased model-based control is linked to stimulant use disorder (<xref ref-type="bibr" rid="bib97">Voon et al., 2015</xref>) and seems to constitute a transdiagnostic dimensional trait related to compulsive behaviour across clinical (<xref ref-type="bibr" rid="bib97">Voon et al., 2015</xref>; <xref ref-type="bibr" rid="bib98">Voon et al., 2017</xref>) and non-clinical populations (<xref ref-type="bibr" rid="bib39">Gillan et al., 2016</xref>). In light of increasing deaths from drug overdoses (<xref ref-type="bibr" rid="bib28">EMCDDA, 2020</xref>; <xref ref-type="bibr" rid="bib83">Seth et al., 2018</xref>), it is important to understand how different neurotransmitter systems affect the competition for cognitive resources when deciding between habitual and goal-directed actions.</p><p>Opiates, psychostimulants, and most other drugs of abuse increase the release of dopamine along the mesolimbic pathway (<xref ref-type="bibr" rid="bib44">Koob and Bloom, 1988</xref>; <xref ref-type="bibr" rid="bib20">Di Chiara, 1999</xref>), a circuit that plays a central role in reinforcement learning (<xref ref-type="bibr" rid="bib81">Schultz et al., 1997</xref>). On top of this, the reinforcing properties of addictive drugs also depend on their ability to activate the µ opioid receptors (<xref ref-type="bibr" rid="bib55">Le Merrer et al., 2009</xref>; <xref ref-type="bibr" rid="bib7">Benjamin et al., 1993</xref>; <xref ref-type="bibr" rid="bib6">Becker et al., 2002</xref>). This suggests that both the dopamine and the opioid systems might be particularly relevant in model-free reinforcement learning processes that drive the formation of habitual behaviour. Studies in rodents show that activating receptors of both systems across the striatum increases cue-triggered wanting of rewards (<xref ref-type="bibr" rid="bib74">Peciña and Berridge, 2013</xref>; <xref ref-type="bibr" rid="bib85">Soares-Cunha et al., 2016</xref>). Conversely, inhibition of both D1-type and D2-type dopamine receptors (referred to as D1 and D2 from here on) as well as opioid receptors reduces motivation to obtain or consume rewards (<xref ref-type="bibr" rid="bib85">Soares-Cunha et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Laurent et al., 2012</xref>; <xref ref-type="bibr" rid="bib73">Peciña, 2008</xref>). This data raises the hypothesis that the drift towards habitual control is enabled by dopamine and opioid receptors via a common neural pathway.</p><p>Recent work in humans provides some evidence in this direction, whereby systemic administration of opioid and D2 dopamine receptor antagonists causes a comparable reduction of cue responsivity and reward impulsivity (<xref ref-type="bibr" rid="bib101">Weber et al., 2016</xref>) and decreases the effort to obtain immediate primary rewards (<xref ref-type="bibr" rid="bib48">Korb et al., 2020</xref>). This suggests that when allocating control between the model-based and model-free system, dopamine or opioid receptor antagonists might comparatively disrupt model-free behavioural strategies and increase model-based behaviour. Yet, no study in humans has directly investigated this. Furthermore, disrupting habit formation might not in itself lead to increased model-based control, without either increasing the perceived value of applying cognitive control or decreasing the cost of doing so.</p><p>Crucially, there are important differences in how each of the two neurochemical systems relate to the types of cognitive control that are pivotal for model-based behaviour. Across a wide range of studies using various dosing schemes, opioid receptor antagonists did not have an effect on tasks in which exertion of cognitive control plays a key role, such as working memory (<xref ref-type="bibr" rid="bib31">File and Silverstone, 1981</xref>; <xref ref-type="bibr" rid="bib96">Volavka et al., 1979</xref>; <xref ref-type="bibr" rid="bib58">Martín del Campo et al., 1992</xref>), sustained attention (<xref ref-type="bibr" rid="bib109">Zacny et al., 1994</xref>), or mathematical problem-solving (<xref ref-type="bibr" rid="bib58">Martín del Campo et al., 1992</xref>) (see <xref ref-type="bibr" rid="bib94">van Steenbergen et al., 2019</xref> for a review). Dopaminergic circuits, on the other hand, are central in a variety of higher cognitive functions and goal-directed behaviour (<xref ref-type="bibr" rid="bib8">Brozoski et al., 1979</xref>). In particular, D1 dopamine receptors in the prefrontal cortex enable the maintenance of goal-relevant information and working memory (<xref ref-type="bibr" rid="bib93">van Schouwenburg et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Sawaguchi and Goldman-Rakic, 1991</xref>; <xref ref-type="bibr" rid="bib104">Williams and Goldman-Rakic, 1995</xref>; <xref ref-type="bibr" rid="bib40">Goldman-Rakic, 1997</xref>), while the D2 dopamine receptor activity disrupts prefrontal representations (<xref ref-type="bibr" rid="bib25">Durstewitz and Seamans, 2008</xref>). In support of this, decreased working memory performance was observed after blocking prefrontal D1, but not prefrontal D2 receptors (<xref ref-type="bibr" rid="bib79">Sawaguchi and Goldman-Rakic, 1991</xref>; <xref ref-type="bibr" rid="bib4">Arnsten, 2011</xref>; <xref ref-type="bibr" rid="bib82">Seamans and Yang, 2004</xref>). In humans, systemic administration of D2 antagonism increased the ability to maintain and manipulate working memory representations (<xref ref-type="bibr" rid="bib22">Dodds et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">Frank and O’Reilly, 2006</xref>) and increased the value of applying cognitive effort (<xref ref-type="bibr" rid="bib102">Westbrook et al., 2020</xref>). This data suggests that blocking D2 receptors, in contrast to blocking opioid receptors, could further facilitate model-based behaviour by enabling or encouraging flexible use of cognitive control.</p><p>This study compared the effects of the highly selective D2/3 dopamine receptor antagonist amisulpride with the opioid receptor antagonist naltrexone on the model-based/model-free trade-off in healthy volunteers. We tested 112 participants with a deterministic version of the two-step task (<xref ref-type="bibr" rid="bib13">Daw et al., 2005</xref>; <xref ref-type="bibr" rid="bib45">Kool et al., 2016</xref>), at baseline and after administering amisulpride (N=38, 400 mg), naltrexone (N=39, 50 mg), or placebo (N=35) in a randomized, double-blind, between-subject design (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Based on the assumption that the dopamine and opioid systems support the allocation of control between habitual and goal-directed systems through overlapping neural circuits, we expected both antagonists to comparatively increase model-based relative to model-free behaviour. Furthermore, based on the hypothesis that blocking D2 receptors affects the cost/benefit analysis of applying the model-based strategy, we expected a stronger shift towards model-based behaviour following amisulpride administration.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Study Procedure.</title><p>After an initial online screening, participants were invited to the lab for a first visit (Session 1), where they were subjected to a medical check-up, before playing the two-step task for the first time. If they fulfilled the study criteria, they were invited for another visit (Session 2), where they received either 400 mg of amisulpride, 50 mg of naltrexone, or placebo (mannitol). After 180 min of waiting time, participants started with the test battery. Approximately 270 min after drug intake, participants performed the two-step task the second time, followed by a Reading Span (working memory) task, and a blood draw to determine amisulpride serum levels.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79661-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Side effects.</title><p>On most measures most participants rated the severity of the side effect as low as possible. The only measures where more than 50% of data points were above 1 was tiredness. Here, the effect of amisulpride was at trend level (b=0.20, p=0.06) and not significant for naltrexone (b=–0.15, p=0.17).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79661-fig1-figsupp1-v1.tif"/></fig></fig-group><p>The two-step task used to assess the model-based/model-free trade-off is a well-established incentivized paradigm, where participants need to make choices in the first stage, which influence their outcomes in the second stage. Each trial of the task starts in one of two possible first-stage states, each featuring a pair of spaceships (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). Upon choosing a spaceship, participants were taken to one of two planets in the second stage, where they encountered an alien that gave them points, which were converted to money at the end of the experiment. In each pair of spaceships, one spaceship flew to the red planet and one to the green. This deterministic mapping from spaceships to planets, as well as which spaceships were paired together, stayed constant throughout the task. However, the points received on each planet changed independently with a Gaussian random walk. When playing the game, participants could therefore simply repeat the choice of spaceship that previously led to positive outcomes, regardless of which planet it was associated with (model-free behaviour, <xref ref-type="fig" rid="fig2">Figure 2b</xref>). Or they could attempt to remember which spaceship flew to which planet and choose the spaceship based on its associated planet (model-based behaviour, <xref ref-type="fig" rid="fig2">Figure 2b</xref>). The task tries to mimic real-life decision-making dilemmas, where we can use our knowledge about the world (e.g., a potentially dangerous virus is circulating) to override a habitual action (e.g., shaking hands when greeting someone) with a more appropriate one (e.g., greeting with an elbow bump or a bow).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Task Design and Hypotheses.</title><p>(<bold>a</bold>) In the first stage of the trial, the participants were presented with one of the two pairs of spaceships. Each of the spaceships flew to one of two planets in the second stage, where they encountered an alien that gave them points. The transition from each of the four spaceships to the planets was deterministic and stayed the same throughout the experiment. The points each alien gave changed independently according to a discretized Gaussian random walk with bouncing boundaries at –4 and 5. (<bold>b</bold>) Behaviour in the task showcasing trials where the previous first-stage state (spaceship pair) was the same (trial 2) and trials where it was different (trial 3). High number of points should encourage choosing the spaceship that flies to the same planet, what we term as ‘staying with the previous choice’. Note that in the featured example, the participant after receiving –1 point in the trial 1 opted against staying with the previous choice in the next trial, and after receiving 2 points in trial 2 opted for staying with the previous choice, by choosing the spaceship, that flew to the same planet.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79661-fig2-v1.tif"/></fig><p>As an initial straightforward approach to dissociate model-based and model-free behaviour, we first examined how previous reward points affected the probability to stay with the previous choice. We then turned to computational modelling and explicitly modelled the relative weight, <inline-formula><mml:math id="inf1"><mml:mi>ω</mml:mi></mml:math></inline-formula>, of model-based compared to model-free behaviour and disentangled it from other processes that might affect participants’ choices, such as exploration and reward devaluation. To assess any effects of the two pharmacological compounds on cognitive control, we also collected data on working memory performance through the Reading Span task (<xref ref-type="bibr" rid="bib43">Klaus and Schriefers, 2016</xref>). We also aimed to control for changes in mood through a mood questionnaire delivered at drug intake and 3 hr later. Whereas the dose we chose for naltrexone provides sufficient occupancy of opioid receptors, the dose for amisulpride is limited by the potentially detrimental side-effects of D2 antagonists (<xref ref-type="bibr" rid="bib90">Takano et al., 2006</xref>). To explore the variance of drug effects across participants, we examined amisulpride serum levels in the blood. Finally, previous research implicated several genotypes related to baseline dopamine function in model-based/model-free behaviour. To control for these baseline differences and to explore potential genotype drug interactions, we collected data on four genetic markers related to prefrontal and striatal dopamine levels. The data and the analysis scripts are available open-access at <ext-link ext-link-type="uri" xlink:href="https://github.com/nacemikus/mbmf-da-op">https://github.com/nacemikus/mbmf-da-op</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:47f15ecdba3571787c7da237ce64f09a3a6afef6;origin=https://github.com/nacemikus/mbmf-da-op;visit=swh:1:snp:9490c0a2d0cad62b71a32f2a692ec91b8fb3626b;anchor=swh:1:rev:4822b12aa33d8e5eb60d8ad5af2a0d3392e00e20">swh:1:rev:4822b12aa33d8e5eb60d8ad5af2a0d3392e00e20</ext-link>; <xref ref-type="bibr" rid="bib64">Mikus, 2022</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Effects of dopaminergic and opioidergic antagonism on staying with previous choices</title><p>One way to quantify the trade-off between the two systems is by looking at the interaction effect of previous points on staying behaviour in trials where knowledge about the task structure is irrelevant (same first stage state as in the previous trial) with trials where it is relevant (different first stage states as in the previous trial). With this, we control for more general effects of the drugs on decision-making behaviour and isolate the effect on the allocation of control between the two systems. As evident from <xref ref-type="fig" rid="fig3">Figure 3</xref> (and <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>), previous points increased the likelihood to stay with the previous choice (<inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> = 0.391), with a 95% credible interval (CI) [0.238, 0.542], and the proportion of the interval below zero P(<inline-formula><mml:math id="inf3"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt;0)&lt;10e-3), however, this was significantly less the case in trials with different compared to the same first stage states (<inline-formula><mml:math id="inf4"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> = −0.186 (95% CI [-0.321,–0.051], P(<inline-formula><mml:math id="inf5"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &gt;0)&lt;0.005). This indicates that participants often failed to consider the mapping from spaceship to planets when making choices in trials where the first stage state differed from the previous trial.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Behavioural analysis.</title><p>(<bold>a</bold>) We used a hierarchical Bayesian logistic regression model to analyse how the probability to stay with the previous choice depended on previous points, previous first-stage state, session, and drug administration and their interaction. We allowed the intercept and the slopes for previous first-stage state and session to vary by participant (full table of coefficients in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). Points and error bars depict mean proportions and standard errors in trials where the participants stayed with their previous choice for each previous point averaged within session and drug group. Lines and ribbons depict the mean estimates and 80% credible intervals. When encountering a trial with the same first-stage state as in its preceding trial, participants were 1.495 times (95% CI [1.286, 1.739], P(<inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt; 0)&lt;10e-3) more likely to stay with their previous choice for each additional previous point (<inline-formula><mml:math id="inf7"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> = 0.402, 95% CI [0.251, 0.553], P(<inline-formula><mml:math id="inf8"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt; 0)&lt;10e-3). In contrast, in trials where the first-stage state was different from the preceding trial, the odds (on the logarithmic scale) of repeating the previous choice of spaceship were reduced, with each additional point earned in the previous trial, by –0.204 (95% CI [–0.263, –0.146], P(<inline-formula><mml:math id="inf9"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &gt; 0)&lt;10e-3), and participants were only 1.219 times (95% CI [1.053, 1.410], P(<inline-formula><mml:math id="inf10"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt; 0)&lt;10e-3) more likely to stay with their choice for each additional previous point. This indicates that participants often failed to consider the mapping from spaceship to planets when making choices in trials where the first-stage state differed from the previous trial. The effects of the drugs can be seen by the different slopes of previous points in the two sessions depicted for both trial types. (<bold>b</bold>) Differences in staying behaviour between sessions, binned into five different reward levels for clarity. Means with standard errors overlayed with means and 80% CI of estimated posterior distributions. (<bold>c</bold>) Means with 80% and 95% CIs of effect sizes (in logodds space) of selected regression coefficients of the hierarchical logistic regression model predicting staying behaviour from previous points (PrevPoints), previous first-stage states (PrevState), session, drug administrations, and all the interactions between them. Ami, amisulpride, n = 38; Nal, naltrexone, n = 39; Pla, placebo, n = 35.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79661-fig3-v1.tif"/></fig><p>Compared to placebo, amisulpride significantly increased the difference between the effects of previous points on staying behaviour in different vs same first state trials, as indicated by a significant four-way interaction (<inline-formula><mml:math id="inf11"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> 0.176, 95% CI [0.036, 0.351], P(<inline-formula><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt;0)&lt;0.007, <xref ref-type="fig" rid="fig3">Figure 3</xref>). When looking at each type of trial separately, we found that amisulpride also decreased the effect of previous reward points on the probability to stay when the first-stage state was the same (<inline-formula><mml:math id="inf13"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>=−0.140, 95% [CI=−0.274,,–0.009], P(<inline-formula><mml:math id="inf14"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &gt;0=0.02)), and slightly (and non-significantly) increased it when the first-stage state was different (<inline-formula><mml:math id="inf15"><mml:msub><mml:mrow><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:math></inline-formula> 0.036 (95% CI –0.091, 0.158), P(<inline-formula><mml:math id="inf16"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt;0)=0.285). For naltrexone, the log odds estimate of the four-way interaction coefficient was centred around 0.016, (95% CI [–0.127, 0.159], P(<inline-formula><mml:math id="inf17"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt;0)=0.41), indicating no marked difference between trial types; there were also no significant differences when looking at each trial-type separately (all p&gt;0.32).</p><p>These results suggest that naltrexone did not affect the trade-off between goal-directed and habitual behaviour in this task. Amisulpride, on the other hand, increased performance in trials where keeping track of the mapping between spaceships and planets was advantageous, compared to those where it was not. However, somewhat counterintuitively, amisulpride also had a seemingly detrimental effect on decision-making overall, as indicated by the reduced effect of previous points on staying behaviour in trials with the same first-stage state. This pattern of behaviour might be due amisulpride’s effect on both model-based/model-free behaviour and other decision-making processes, such as the tendency to explore other options. We note also that this analysis approach ignores one important aspect of the task, namely that subjects were comparing the relative points between two independently changing planets, thereby the points received in each trial should be seen in relation to the points that the participants expected to get were they to choose the other spaceship. To address these issues, we employed computational modelling.</p></sec><sec id="s2-2"><title>Estimation of drug effects with computational modelling</title><p>We defined a model (M1) where, similarly to the computational models previously used with this task (<xref ref-type="bibr" rid="bib46">Kool et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Kool et al., 2016</xref>), the trade-off between the goal-directed and habitual components is captured by the weighting parameter <inline-formula><mml:math id="inf18"><mml:mi>ω</mml:mi></mml:math></inline-formula>, which embodies the degree to which the choice of participants on each trial is influenced by model-based (<inline-formula><mml:math id="inf19"><mml:mi>ω</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula>), or model-free (<inline-formula><mml:math id="inf20"><mml:mi>ω</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>) subjective values of each of the spaceships. In this model, the subjective values of both the model-free and the model-based model components are defined as the last observed outcome following the choice of that spaceship. The crucial difference between the two components is that, whereas the model-free agent learns only by experiencing direct outcomes of spaceship selection, the model-based component always considers the deterministic mapping from spaceships to planets, and thus learns the subjective values of planets. We also include an inverse temperature parameter <inline-formula><mml:math id="inf21"><mml:mi>η</mml:mi></mml:math></inline-formula> (lower <inline-formula><mml:math id="inf22"><mml:mi>η</mml:mi></mml:math></inline-formula> indicates more explorative or noisy behaviour) and a <italic>discounting parameter</italic> <inline-formula><mml:math id="inf23"><mml:mi>γ</mml:mi></mml:math></inline-formula> that marks the degree of devaluation of non-chosen (and non-encountered) spaceships for the model-free component in each trial.</p><p>We compared the above-described model to two Dual-systems Reinforcement Learning (RL) models (Fig. S1a). In these two models, the degree to which an outcome in each trial affects the subjective values of actions at each stage is determined by a learning rate parameter. The model-free agent thus learns the subjective action values in each stage from experience, by increasing the values of actions and states that lead to outcomes that were better than expected and decreasing the values when the outcome was worse than expected. We allow the learning rate at both stages to either be different (model M2) or the same (model M3). Note, that the model M1 is version of these RL model, where the learning rates are set to 1 and a devaluation parameter is included on the non-chosen option. This is motivated by the observation that the rewards change according to a Gaussian random walk (and are not probabilistic), and therefore the last encountered outcome is the best guess the agent can make. When comparing the performance of the three models we found that the model M1 has better out of sample predictive accuracy compared to the other two models (Fig. S1b). We verified the winning model with parameter recovery (Fig. S1c) and posterior predictive checks (Fig. S1d–f).</p><p>We first observed that the more model-based choices the participants made, the more money they earned (<inline-formula><mml:math id="inf24"><mml:mi>r</mml:mi></mml:math></inline-formula>=0.65, 95% CI [0.53, 0.76]). This serves as a validity check of the task, which was designed to make cognitive control pay off (literally) (<xref ref-type="bibr" rid="bib45">Kool et al., 2016</xref>). We then looked at how the model parameters relate to the random slopes from the behavioural analysis of staying behaviour and found that the participant-level (random effect) slope for the effect of previous points on staying behaviour in different vs same first state trials was most strongly related to <inline-formula><mml:math id="inf25"><mml:mi>ω</mml:mi></mml:math></inline-formula> (d=0.493, p&lt;10e-3) and negatively related to the inverse temperature parameter <inline-formula><mml:math id="inf26"><mml:mi>η</mml:mi></mml:math></inline-formula> (d=–0.328, p&lt;10e-3), and the slope for trials with same first states was mostly related to <inline-formula><mml:math id="inf27"><mml:mi>η</mml:mi></mml:math></inline-formula> (d=0.822, p&lt;10e-3), and less so to <inline-formula><mml:math id="inf28"><mml:mi>ω</mml:mi></mml:math></inline-formula> (d=0.235, p&lt;10e-3).</p></sec><sec id="s2-3"><title>Dopaminergic antagonism increases model-based relative to model free control</title><p>We embedded the model parameter estimation within a hierarchical Bayesian inference framework and estimated the drug effects on all three parameters in one model (<xref ref-type="bibr" rid="bib110">Zhang et al., 2020</xref>). We found that under amisulpride the difference in <inline-formula><mml:math id="inf29"><mml:mi>ω</mml:mi></mml:math></inline-formula> between the two sessions is higher than in the placebo group (<inline-formula><mml:math id="inf30"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ω</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> = 0.787, 95% CI [0.131, 1.510], P(<inline-formula><mml:math id="inf31"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ω</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> &lt;0)=0.010, <xref ref-type="fig" rid="fig4">Figure 4a</xref>), with effect size d=0.758, (95% CI [0.126, 1.455]). In contrast, there was no session difference in <inline-formula><mml:math id="inf32"><mml:mi>ω</mml:mi></mml:math></inline-formula> between naltrexone and placebo (<inline-formula><mml:math id="inf33"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> = 0.238, 95% CI [–0.443, 0.856], P(<inline-formula><mml:math id="inf34"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> &lt;0)=0.250), with a marginally significant difference with a moderate effect size between the effects of the two compounds (<inline-formula><mml:math id="inf35"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ω</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> = 0.578, 95% CI [–0.108, 1.337], P(<inline-formula><mml:math id="inf36"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ω</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> &lt;0)=0.046, d=0.557, 95% CI [–0.104, 1.289]).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Effects of amisulpride and naltrexone on the model parameters.</title><p>The best performing model (<bold>M1</bold>) is described with three free parameters, <inline-formula><mml:math id="inf37"><mml:mi>ω</mml:mi></mml:math></inline-formula> (the degree of model-based vs model-free value contributions to choice), <inline-formula><mml:math id="inf38"><mml:mi>γ</mml:mi></mml:math></inline-formula> (the degree of devaluation of unencountered spaceships), and <inline-formula><mml:math id="inf39"><mml:mi>η</mml:mi></mml:math></inline-formula> (the inverse temperature in the softmax mapping from values to probabilities). The parameters for both sessions and effects of drug treatments were estimated in one hierarchical model. (<bold>a</bold>) Going from session 1 to session 2, amisulpride administration led to higher estimations of <inline-formula><mml:math id="inf40"><mml:mi>ω</mml:mi></mml:math></inline-formula>, and therefore increased model-based relative to model-free control. The difference between sessions of the model-based weights is shown in parameter estimation space (hence the prime). (<bold>b</bold>) Difference in the parameter <inline-formula><mml:math id="inf41"><mml:mi>γ</mml:mi><mml:mo>.</mml:mo></mml:math></inline-formula> (<bold>c</bold>) Difference in the inverse temperature parameter <inline-formula><mml:math id="inf42"><mml:mi>η</mml:mi></mml:math></inline-formula>. Lower values mean higher exploration. (<bold>d</bold>) Posterior distributions of the effect of drugs, compared to placebo, on group-level mean session differences. Effect sizes with 80% and 95% CI. Ami, amisulpride, n = 38; Nal, naltrexone, n = 39; Pla, placebo, n = 35.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79661-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Computational modelling.</title><p>(<bold>a</bold>) We compared our model to two dual-system reinforcement learning (RL) models used previously with this task (<xref ref-type="bibr" rid="bib46">Kool et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Kool et al., 2016</xref>). In model M1 both model-free and model-based agents remember only the last outcome of a choice of spaceships, but only the model-based agent is aware of the relation between first-stage states. Models M2 and M3 are reinforcement learning-based models adapted from <xref ref-type="bibr" rid="bib45">Kool et al., 2016</xref> with either separate (M2) or equal (M3) first and second stage learning rates. (<bold>b</bold>) Models were compared using the leave-one-out information criterion (looic), where lower values indicate better out of sample trial-by-trial predictive performance. Refer to the Methods for weights from Bayesian Model Averaging of all models, indicating the posterior probability of each model given the data. Model M1 performs best in both metrics. (<bold>c</bold>) For the winning model (M1) we calculated the posterior predictive accuracy averaged within participants and found that the mean (SD) posterior prediction accuracy was 65% (11%). (<bold>d</bold>) Parameter recovery. (<bold>e</bold>) Simulated data plotted to visually and statistically investigate whether the model captures the crucial aspects of behaviour and group differences (compared to <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79661-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Results of the model including stickiness parameters.</title><p>Posterior distribution of effect sizes of group level effects on model parameters in a model including stickiness parameters with means, 95 and 80% intervals.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79661-fig4-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Dopaminergic antagonism increases the exploration parameter in participants with high serum levels</title><p>We found no evidence that either the blockade of dopamine D2 or opioid receptors influenced the devaluation parameter <inline-formula><mml:math id="inf43"><mml:mi>γ</mml:mi></mml:math></inline-formula> (<xref ref-type="fig" rid="fig4">Figure 4c and d</xref>, <inline-formula><mml:math id="inf44"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>=0.01, 95% CI [–1.00, 1.00], <inline-formula><mml:math id="inf45"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula>=0.07, 95% CI [–0.88, 1.02]). However, we found some evidence for amisulpride effects on the inverse temperature parameter <inline-formula><mml:math id="inf46"><mml:mi>η</mml:mi></mml:math></inline-formula> (<xref ref-type="fig" rid="fig4">Figure 4b and d</xref>, <inline-formula><mml:math id="inf47"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> = –0.33, 95% CI [–0.67, 0.02], P(<inline-formula><mml:math id="inf48"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> &gt;0)=0.034, d=–0.38, 95% CI [–0.78, 0.03]). This would imply that amisulpride increases ‘explorative’ choices or choices that the model would not predict based on estimated action values. To verify if our model performs worse for the amisulpride group we looked at how the pharmacological treatment predicts out-of-sample prediction accuracy and found no differences between groups (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1 and f</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). We also note that the differences between sessions in <inline-formula><mml:math id="inf49"><mml:mi>ω</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf50"><mml:mi>η</mml:mi></mml:math></inline-formula> are not negatively correlated (<italic>r</italic>=0.12, 95% CI [–0.06, 0.30]), suggesting that the two effects are not related to each other.</p><p>We next looked at whether the effects of amisulpride were different based on the effective dose. We reran the parameter estimation including a variable for amisulpride blood serum levels as a group-level covariate in the hierarchical model (<xref ref-type="fig" rid="fig5">Figure 5</xref>). We used a categorical variable due to the highly skewed distribution of serum levels (<xref ref-type="bibr" rid="bib17">DeCoster et al., 2011</xref>) (see Methods for details). We found that amisulpride increased <inline-formula><mml:math id="inf51"><mml:mi>ω</mml:mi></mml:math></inline-formula> in both the low serum group (b=0.919, 95% CI [0.216, 1.722], P(b&lt;0)=0.006, d=1.013, 95% CI [0.238, 1.897]) and the high serum group (b=0.872, 95% CI [0.008, 1.853], P(b&lt;0)=0.024, d=0.961, 95% CI [0.009, 2.041]), with no difference between the effects (P(b&gt;0)=0.458). However, when looking at the effects of amisulpride on <inline-formula><mml:math id="inf52"><mml:mi>η</mml:mi></mml:math></inline-formula> we found that it was not reduced in the low serum group (b=–0.105, 95% CI [–0.523, 0.348], P(b&gt;0)=0.323, d=–0.096, 95% CI [–0.477, 0.317]), but was reduced in the high serum group (b=–0.492, 95% CI [–0.96,–0.033], P(b&gt;0)=0.018, d=–0.45, 95% CI [–0.877,–0.03]), with a (non-significant) moderate effect size difference between the effects (b=–0.393, 95% CI [–0.918, 0.118], P(b&gt;0)=0.066, d=–0.359, 95% CI [–0.838, 0.108]).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Effects of amisulpride across the high and low blood serum levels.</title><p>(<bold>a</bold>) Across both effective dose groups of participants, amisulpride increased the model-free/model-based weight parameter. (<bold>b</bold>) Amisulpride increased exploration (decreased <inline-formula><mml:math id="inf53"><mml:mi>η</mml:mi></mml:math></inline-formula>) in the group that had high blood serum levels, but not in the group with low serum levels. Effect sizes with 80% and 95% CI. Ami, amisulpride; n = 32 (low serum, n = 14, high serum, n = 18); Nal, naltrexone, n = 39; Pla, placebo, n = 35.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79661-fig5-v1.tif"/></fig><p>We also reran the behavioural analysis, predicting the likelihood to stay with the previous choice as before, but including the serum variable. In line with the results from the computational model, we found that amisulpride significantly increased the difference between the effects of previous points on staying behaviour in different vs same first state trials both in the low serum group (<inline-formula><mml:math id="inf54"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> = 0.235, 95% CI [0.047, 0.43], P(<inline-formula><mml:math id="inf55"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt;0)=0.006), as well as in the high serum group, although to a lesser extent (<inline-formula><mml:math id="inf56"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> = 0.143, 95% CI [–0.03, 0.323], P(<inline-formula><mml:math id="inf57"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &lt;0)=0.054). Conversely, in the high serum group, amisulpride decreased the effect of previous points in the same first state trials (b=–0.172, 95% CI [-0.34,–0.002], P(<inline-formula><mml:math id="inf58"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &gt;0)=0.024), mirroring the effect of the computational model. In the low serum group, amisulpride also decreased the effect of previous points on staying behaviour in the first state trials (<inline-formula><mml:math id="inf59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> = –0.147, 95% CI [–0.34, 0.036], P(<inline-formula><mml:math id="inf60"><mml:msub><mml:mrow><mml:mi mathvariant="normal">β</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>d</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> &gt;0)=0.060). Note that, although the 95% CI contained values above 0, this represents a slight inconsistency with the results from the computational model, where the exploration parameter <inline-formula><mml:math id="inf61"><mml:mi>η</mml:mi></mml:math></inline-formula> was not reliably reduced in the low serum group.</p><p>Lower values of <inline-formula><mml:math id="inf62"><mml:mi>η</mml:mi></mml:math></inline-formula> as well as lower effect of previous points on behaviour implies that participants behaviour more stochastically (or noisily) and that the computational model cannot explain that behaviour based on estimated values of the two spaceships. To see whether some of the increased variances can be explained by the tendency of participants to repeat actions or choices regardless of outcomes, we extended the M1 serum model to include a response stickiness (<inline-formula><mml:math id="inf63"><mml:mi>ρ</mml:mi></mml:math></inline-formula>) and stimulus stickiness (<inline-formula><mml:math id="inf64"><mml:mi>π</mml:mi></mml:math></inline-formula>) parameter. We found some evidence that amisulpride in participants with high serum levels increased switching between responses, as indicated by the reduced <inline-formula><mml:math id="inf65"><mml:mi>ρ</mml:mi></mml:math></inline-formula> parameter (b=–0.466, 95% CI [–0.962, 0.043], P(b&gt;0)=0.039). This effect was not present in the low serum group (b=–0.158, 95% CI [–0.618, 0.311], P(b&gt;0)=0.251), with a non-significant difference between the effects (b=–0.294, 95% CI [–0.723, 0.13], P(b&gt;0)=0.082). The inclusion of the two stickiness parameters did not markedly change the posterior distributions of effects of amisulpride on <inline-formula><mml:math id="inf66"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, but did reduce the effect on <inline-formula><mml:math id="inf67"><mml:mi>ω</mml:mi></mml:math></inline-formula> in the high serum group (b=0.571, 95% CI [–0.361, 1.527], P(b&lt;0)=0.111, see <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> for other relevant posterior distributions). We note, however, that the model including stickiness parameters performed worse than the model without the stickiness parameters, with a lower out-of-sample trial-wise predictive performance (<inline-formula><mml:math id="inf68"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>p</mml:mi><mml:mi>d</mml:mi></mml:math></inline-formula> (sd) = –413 (31.5)).</p></sec><sec id="s2-5"><title>Working memory, mood, and genetics</title><p>To examine whether working memory capacity was affected by our drug manipulation, we analysed performance in the Reading Span task and found no evidence for drug effects on proportion of correct recalls (<inline-formula><mml:math id="inf69"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>w</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> = –0.02, 95% CI [–0.07, 0.02], <inline-formula><mml:math id="inf70"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>w</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> = –0.03, 95% CI [–0.08, 0.02]). We also found no difference in mood changes following amisulpride administration from drug intake and 3 hr in either serum group (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1cd and e</xref>), but found that naltrexone flattened both positive (b=–0.411, 95% CI [–0.855, 0.029], P(b&gt;0)=0.035) and negative affect (b=–0.524, 95% CI [-1.001,–0.061], P(b&gt;0)=0.013). To explore what other group level variables might influence the drug effects, we ran two linear models predicting differences in <inline-formula><mml:math id="inf71"><mml:mi>ω</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf72"><mml:mi>η</mml:mi></mml:math></inline-formula> between sessions including working memory and mood ratings as covariates in the analysis and Sex, Weight and Age as moderator variables. We found no significant effects and neither did conditioning on the covariates affect inference of drug effects on <inline-formula><mml:math id="inf73"><mml:mi>ω</mml:mi></mml:math></inline-formula> or <inline-formula><mml:math id="inf74"><mml:mi>η</mml:mi></mml:math></inline-formula> (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f and g</xref>).</p><p>We also found no robust effects of genotype variables on either baseline measures or on the drug effects on either <inline-formula><mml:math id="inf75"><mml:mi>ω</mml:mi></mml:math></inline-formula> or <inline-formula><mml:math id="inf76"><mml:mi>η</mml:mi></mml:math></inline-formula> (Supplementary Files h, i). In line with previous studies using similar paradigms, we used the <italic>COMT</italic> single nucleotide polymorphism (SNP) as a marker for prefrontal dopamine function, and <italic>DARPP-32</italic> SNP as a marker of striatal D1 receptor function (<xref ref-type="bibr" rid="bib24">Doll et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Männistö and Kaakkola, 1999</xref>; <xref ref-type="bibr" rid="bib91">Trantham-Davidson et al., 2004</xref>). We also investigated two genetic markers for striatal dopamine levels, namely the <italic>Taq1A</italic> SNP and the <italic>DAT1</italic> polymorphism, a 40 base-pair variable number tandem repeat polymorphism (VNTR) of the dopamine transporter (<xref ref-type="bibr" rid="bib51">Laakso et al., 2005</xref>; <xref ref-type="bibr" rid="bib26">Eisenegger et al., 2013</xref>; <xref ref-type="bibr" rid="bib27">Eisenegger et al., 2014</xref>) (see Supplementary Note 1 for details on genotypes and how they relate to striatal and prefrontal dopamine function).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Drugs that stimulate opioid or dopamine neurotransmitter systems can lead to compulsive drug-taking, which can result either from increased reliance on habits or from failures to exert cognitive control over habitual urges. Experimental studies strongly implicate both the dopamine and opioid neurotransmitter systems in processes related to habit formation. Here, we asked whether pharmacologically blocking opioid and dopamine receptors promotes the use of goal-directed over habitual control in healthy volunteers. Using the two-step task and a novel computational model, we found that blocking D2-like dopamine receptors increases the weight on model-based relative to model-free control, whereas blocking opioid receptors has no appreciable effect, with a marginally significant difference between the effects (with a moderate average effect size). Additionally, we found that amisulpride increases choice exploration, particularly in the group of participants with high amisulpride serum levels in the blood. The results from the computational model mirrored those obtained when analysing the effects of previous points on staying with prior choices. The degree to which reward in a previous trial affected choice repetition in trials with the same first stage states was mostly related to the exploitation/exploration parameter in the model and was reduced under amisulpride. Conversely, the relative increase in the effect of previous points on choice repetition between different vs same first stage state trials was more related to the model-based/model-free weight and was increased under amisulpride. Our findings provide initial evidence for a divergent involvement of the dopamine and opioid neurotransmitter systems in the shift between habitual and goal-directed behaviour. The lack of effects of naltrexone on the model-based/model-free trade-off also provides some support for the notion that simply disrupting neurobiological systems that subserve habitual behaviour might not be enough to increase goal-directed behaviour in this task. An increase in the model-based/model-free weight following amisulpride administration advocates for dopamine playing a decisive role in flexibly applying cognitive control to facilitate model-based behaviour and highlights the specific functional contribution of the D2 receptor subtype.</p><p>Prior research on dopamine’s involvement in the arbitration between the two systems has produced inconsistent results. Elevated dopamine levels, either at baseline or following pharmacological treatments such as L-dopa, are related to increased model-based behaviour in some studies (<xref ref-type="bibr" rid="bib107">Wunderlich et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Deserno et al., 2015</xref>; <xref ref-type="bibr" rid="bib84">Sharp et al., 2016</xref>), but show no correlation or even opposite effects in others (<xref ref-type="bibr" rid="bib49">Kroemer et al., 2019</xref>; <xref ref-type="bibr" rid="bib99">Voon et al., 2020</xref>). This suggests that the effect of dopamine promoting agents on model-based/model-free trade-off might depend on the relative contributions of the various region-specific dopamine receptor subtypes. Studies have repeatedly shown that prefrontal dopamine circuits enable goal stability and distractor avoidance, primarily through D1 dopamine receptors (<xref ref-type="bibr" rid="bib93">van Schouwenburg et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Sawaguchi and Goldman-Rakic, 1991</xref>; <xref ref-type="bibr" rid="bib104">Williams and Goldman-Rakic, 1995</xref>). According to the dual-state theory of prefrontal dopamine function (<xref ref-type="bibr" rid="bib25">Durstewitz and Seamans, 2008</xref>), a state dominated by D1 receptor activity is characterized by a high-energy barrier and supports stabilization of prefrontal representations. Conversely, a D2 receptor dominated state has a low-energy barrier and facilitates flexible switching between representational states. In line with this, D2 antagonists impair behaviour in tasks that require constant attentional set shifting (<xref ref-type="bibr" rid="bib62">Mehta et al., 2004</xref>), but might improve performance in tasks where prefrontal goal representations are required (<xref ref-type="bibr" rid="bib42">Kahnt et al., 2015</xref>). For example, D2 antagonism improves the ability of participants in certain cognitive tasks that require manipulation of task-relevant information in the working memory (<xref ref-type="bibr" rid="bib22">Dodds et al., 2009</xref>; <xref ref-type="bibr" rid="bib35">Frank and O’Reilly, 2006</xref>), but does not improve working memory capacity, or memory retrieval (<xref ref-type="bibr" rid="bib22">Dodds et al., 2009</xref>; <xref ref-type="bibr" rid="bib67">Naef et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Mehta et al., 1999</xref>). The effects of D2 antagonism on model-based/model-free behaviour in our study can be interpreted within this framework to result from increased ability to maintain prefrontal representation of the mapping between the spaceships and the planets online. However, this is difficult to reconcile with the fact that model-based behaviour in dynamic learning paradigms, such as the one used here, also requires flexible updating of action values.</p><p>Theories of adaptive control emphasize that the prefrontal regions subserving cognitive control interact with striatal dopaminergic circuits (<xref ref-type="bibr" rid="bib60">McNab and Klingberg, 2008</xref>; <xref ref-type="bibr" rid="bib34">Frank, 2005</xref>). In the striatum, phasic dopaminergic bursts subserve prediction error propagation and action initiation (<xref ref-type="bibr" rid="bib33">Frank et al., 2004</xref>) mainly, but not exclusively, through D1 dopamine receptors (<xref ref-type="bibr" rid="bib85">Soares-Cunha et al., 2016</xref>; <xref ref-type="bibr" rid="bib33">Frank et al., 2004</xref>; <xref ref-type="bibr" rid="bib66">Montague et al., 1996</xref>). Slower baseline dopamine changes in tonic activity are believed to invigorate physical action (<xref ref-type="bibr" rid="bib69">Niv et al., 2007</xref>) based on cost-benefit tradeoffs (<xref ref-type="bibr" rid="bib78">Salamone et al., 2016</xref>). More recent work extended this framework and proposed that the same circuits subserve cost-benefit analysis of applying cognitive effort, framing the role of striatal dopamine as mediating the decision to apply cognitive control based on perceived value vs costs of doing so (<xref ref-type="bibr" rid="bib103">Westbrook et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Cools, 2016</xref>; <xref ref-type="bibr" rid="bib12">Cools, 2019</xref>). In a recent study that combined neurochemical imaging with pharmacological administration of 400 mg of sulpiride (another D2 dopamine receptor antagonist) and methylphenidate (a drug that boosts striatal dopamine availability) showed that both drugs comparatively increased the willingness to exert cognitive effort, particularly in subjects with low striatal dopamine availability (<xref ref-type="bibr" rid="bib102">Westbrook et al., 2020</xref>). An important aspect of drugs that target D2 receptors is that they are known to mainly act on presynaptic D2 receptors at low doses, while binding to postsynaptic receptors prevailingly accounts for their effects at higher doses (<xref ref-type="bibr" rid="bib80">Schoemaker et al., 1997</xref>). Presynaptic D2 receptors are believed to play an autoregulatory control of dopamine signalling through inhibition of synthesis and dopamine release (<xref ref-type="bibr" rid="bib32">Ford, 2014</xref>). In our data, we find that the increase in model-based control did not scale with higher effective doses and was present in participants with either high or low serum levels in the blood. The effect in the high serum group was slightly reduced (and not robustly above zero, p=0.111) in the computational model that included stickiness parameters, although we note that including stickiness parameters led to a poorer model fit. Taken together, this provides some evidence for the notion that the effects of amisulpride on model-based behaviour are not driven by postsynaptic effects but might rather be due to amisulpride increasing dopamine levels through presynaptic D2 receptor blockade and thereby boosting the willingness to apply cognitive effort.</p><p>Interestingly, amisulpride also increased choice stochasticity parametrised by the softmax inverse temperature parameter. In a paradigm with two choice options, it cannot be definitively determined whether this indicates higher decision-noise or increased exploration of alternative choices. We can however speculate that increased decision noise would lead to overall detrimental effects on learning in both trial types with same and different consecutive first stage states, which we do not observe in our data. The effect on the choice stochasticity parameter was only present in participants with a higher effective dose (<xref ref-type="bibr" rid="bib77">Rosenzweig et al., 2002</xref>), suggesting that the effect was more likely to be post-synaptic. Similarly, in the same effective dose group, we found some evidence that amisulpride reduces response stickiness indicating increased switching between actions. This is well in line with a prominent model of the cortico-striatal circuitry implicating post-synaptic D2 receptors in exploration/exploitation (<xref ref-type="bibr" rid="bib34">Frank, 2005</xref>) and supported by empirical data. In animal studies, activation of D2 receptors was shown to lead to choice perseverance and more deterministic behaviour, whereas D2 receptor inhibition increases the probability of performing competing actions and increases randomness in action selection (<xref ref-type="bibr" rid="bib87">Sridharan et al., 2006</xref>). In humans, a recent neurochemical imaging study showed that D2 receptor availability in the striatum correlated with choice uncertainty parameters across both reinforcement learning and active inference computational modelling frameworks (<xref ref-type="bibr" rid="bib1">Adams et al., 2020</xref>). Increased choice uncertainty was also observed in a social and non-social learning tasks in a study using 800 mg of sulpiride, a dose that is known to exert post-synaptic effects (<xref ref-type="bibr" rid="bib27">Eisenegger et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Mikus et al., 2022</xref>). We note, however, that the evidence for the difference in exploration between the low and high serum groups was not robust (p=0.066). Furthermore, it has been suggested that increased striatal dopamine is also related to tendency for stochastic, undirected exploration (<xref ref-type="bibr" rid="bib38">Gershman and Uchida, 2019</xref>; <xref ref-type="bibr" rid="bib36">Frank et al., 2009</xref>), arising due to overall uncertainty across available options (<xref ref-type="bibr" rid="bib38">Gershman and Uchida, 2019</xref>) or through increasing the opportunity cost of choosing the wrong option (<xref ref-type="bibr" rid="bib69">Niv et al., 2007</xref>; <xref ref-type="bibr" rid="bib11">Cools, 2016</xref>). This suggests that the same biological signature that leads to increased cognitive effort expenditure also promotes choice exploration. In line with this, both prior studies that investigated the effect of increasing dopamine availability with L-DOPA on model-based/model-free behaviour observed increase choice exploration as well as increased model-based behaviour (although in one it was only present in individuals with a higher working memory capacity) (<xref ref-type="bibr" rid="bib107">Wunderlich et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Kroemer et al., 2019</xref>).</p><p>The lack of a pronounced effect of naltrexone on model-based/model-free behaviour is unlikely to be due to issues of dosage or timing, since 50 mg of naltrexone leads to a~90% of µ receptor occupancy even 48 hr post intake (<xref ref-type="bibr" rid="bib54">Lee et al., 1988</xref>; <xref ref-type="bibr" rid="bib92">Trøstheim et al., 2022</xref>), with µ receptors being the primary (but not only) opioid receptor type that the drug binds to. One possibility is that opioid receptors are not crucial for model-free learning required in this task. This is in opposition to previous studies showing that acute administration of naltrexone, comparably to amisulpride, causes a reduction of cue responsivity and reward impulsivity (<xref ref-type="bibr" rid="bib101">Weber et al., 2016</xref>), decreases effort to obtain immediate primary rewards (<xref ref-type="bibr" rid="bib48">Korb et al., 2020</xref>), and decreases the wanting of rewards (<xref ref-type="bibr" rid="bib86">Soutschek et al., 2021</xref>). Similarly, preclinical studies in rats show that naltrexone and naloxone, another opioid antagonist, decreased sucrose reinforced place preference (<xref ref-type="bibr" rid="bib18">Delamater et al., 2000</xref>; <xref ref-type="bibr" rid="bib2">Agmo et al., 1995</xref>). Furthermore, both naltrexone and naloxone are used to reduce craving in patients with substance use disorder (<xref ref-type="bibr" rid="bib76">Quednow and Herdener, 2016</xref>). However, there is also evidence that opioid receptors are important for goal-directed behaviour. In particular, a study in rats showed that opioid receptor blockade leads to decreased sensitivity to reward value and accelerated habitual control of actions (<xref ref-type="bibr" rid="bib100">Wassum et al., 2009</xref>), and in a recent neurochemical imaging study in humans µ opioid receptor availability correlated with goal-directed behaviour in a loss-only version of the two-step task (<xref ref-type="bibr" rid="bib99">Voon et al., 2020</xref>). In fact, opioid agonists (but not antagonists) can in some cases lead to increased performance in cognitive control tasks (<xref ref-type="bibr" rid="bib94">van Steenbergen et al., 2019</xref>). One explanation of our results is that naltrexone simply reduced the intrinsic value of reward and therefore decreased the motivation to exert cognitive effort, which would be in line with the observed flattening of both positive and negative affect after naltrexone administration.</p><p>An important limitation of the experimental approach used here is that it rests on the assumption that there are only two ways of learning, which moreover can be distinguished clearly. This assumption has been questioned in the reinforcement learning literature (<xref ref-type="bibr" rid="bib30">Feher da Silva and Hare, 2020</xref>; <xref ref-type="bibr" rid="bib15">Daw, 2018</xref>), and mirrors the scepticism of the two-system division of decision making in cognitive psychology (<xref ref-type="bibr" rid="bib63">Melnikoff and Bargh, 2018</xref>). Although we made sure that participants understood what the task rules were and how they could maximize their gains, we cannot exclude the possibility that participants searched for alternative models to obtain rewards, such as different pressing patterns or simply favouring one stimulus over the other (<xref ref-type="bibr" rid="bib30">Feher da Silva and Hare, 2020</xref>). In fact, the increased exploration parameter in the amisulpride group could be due to participants’ increased exploration of this model space. Importantly, it should also be acknowledged that the behavioural setup in our study does not allow us to draw definite conclusions about the mechanisms that mediate amisulpride’s effects on model-based or model-free behaviour. For example, it is not clear whether amisulpride increases the perceived benefit of applying cognitive control, or whether it increases the participant’s ability to do so through various possible complementary processes, such as goal maintenance or planning abilities. Future studies should further elucidate the mechanistic contributions of dopamine receptors to the distinct coding and utilisation of task relevant representations (<xref ref-type="bibr" rid="bib52">Langdon et al., 2018</xref>; <xref ref-type="bibr" rid="bib88">Stalnaker et al., 2019</xref>).</p><p>One of the strengths of our design is a baseline measure, and the fact that the participants were all introduced to the task under no administration, thus avoiding potential effects of the treatment on task training. Although this design allowed us to reduce between-subjects variability, we cannot completely exclude order effects. Although unlikely, it is possible that the effects of the treatment that we observe come indirectly from the effects of the two drugs on either skill transfer from the previous session, or simply on the effect of the drugs on the part of the experiment that preceded the task. For instance, participants under amisulpride could be less tired from other tasks and therefore more willing to exert effort in the task presented here. Speaking against this is the observation that we found no differences in mood between amisulpride and placebo regardless of low or high serum levels.</p><p>We note that opioid and dopamine systems are not the only neurotransmitter systems that have been implicated in the model-based/model-free tread-off. Most notably, depletion of the serotonin precursor tryptophane biases behaviour towards habitual and away from goal-directed (<xref ref-type="bibr" rid="bib105">Worbe et al., 2015</xref>), suggesting that serotonin supports goal-directed behaviour. This claim is also in line with a recent neurochemical imaging study that showed that serotonin terminal density in the striatum correlated with higher goal-directed behaviour in a version of the two-step task (<xref ref-type="bibr" rid="bib99">Voon et al., 2020</xref>) and decreasing prefrontal serotonin levels has been shown to promote drug seeking behaviour (<xref ref-type="bibr" rid="bib75">Pelloux et al., 2012</xref>). In light of this, we also note that amisulpride also blocks serotonin receptors, albeit with lower affinity, which should be kept in mind when considering the findings of our study. In conclusion, we provide a first comparison of the contributions of the dopamine D2 and opioid receptors to arbitration between the model-based and model-free systems. Our results suggest that D2 dopamine antagonists might promote goal-directed behaviour when alternative habitual choices are available, already in low doses, while opioid blockade does not have such an effect on model-based behaviour. These findings are a step forward in understanding how neuromodulators control the arbitration between habitual and goal-directed decision-making systems, which can in the long run be crucial for developing targeted pharmacological treatments for addiction and other disorders of compulsivity.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Procedure</title><p>The study took place in the Department of Psychiatry and Psychotherapy at the Medical University of Vienna. After initial online screening, the participants were invited for a first visit, where they underwent a physical examination (electrocardiogram, hemogram) and a psychiatric screening before being subjected to the two-step task that consisted of a 25 min automated training period followed by 200 trials of the task (see <xref ref-type="fig" rid="fig1">Figure 1</xref> for the study outline). Participants eligible for the study were invited back to the clinic approximately 3 weeks after their first visit.</p><p>In their second visit participants received either placebo, 400 mg of amisulpride, or 50 mg of naltrexone. After a waiting period of 3 hr, participants solved two additional tasks (explained elsewhere <xref ref-type="bibr" rid="bib48">Korb et al., 2020</xref>) before performing the two-step task (on average 4 hr 36 min, SD = 22 min, after the pill intake) as well as a working memory task. Waiting times and the doses of drugs were chosen based on previous pharmacological studies with the same compounds (<xref ref-type="bibr" rid="bib101">Weber et al., 2016</xref>). To ensure comparable absorption, participants were asked to come with an empty stomach and received a standardized meal before pill intake. Participants filled out a questionnaire assessing mood and side effects right after pill intake and 3 hr later. There were no profound differences in side effects across the three drug groups, apart from a trend level effect of amisulpride on tiredness (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Blood plasma levels confirmed amisulpride levels above 212.6 µg/l (mean (sd)=548.8 (96.9)), in all participants of the amisulpride group. For 7 subjects serum levels were not possible to calculate due to technical issues with blood samples. For 18 participants the value of amisulpride was at maximum (&gt;604 µg/l), leading to a highly skewed distribution, with no variance in the upper 50% quantile. Because of this, we dichotomized the data into a categorical variable, whereby the high serum group consisted of participants with serum levels above 604 µg/l (n=18) and the low serum group had levels between 212.6 µg/l and 602.5 µg/l (n=14).</p></sec><sec id="s4-2"><title>Participants</title><p>Data were collected from 120 volunteers and constituted a subset of volunteers involved in a larger study (<xref ref-type="bibr" rid="bib48">Korb et al., 2020</xref>). All participants were assigned an initial screening code and a subject ID number. For six participants the task data from the first session were lost due to failures in assigning screening codes from the first session to subject ID numbers in the second. For two participants the task data from the second session were lost owing to technical issues, resulting in 112 participants included in the main analysis (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1l</xref> for exact subject numbers for each analysis). All participants had no history of drug abuse or other psychiatric disorders and were matched in age, sex, and BMI (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1j</xref>). The study was approved by the Ethical Committee of the Medical University of Vienna (EK N. 1393/2017) and was in line with the Declaration of Helsinki (<xref ref-type="bibr" rid="bib106">World Medical association Declaration of Helsinki, 2013</xref>). Participants received a monetary compensation of 90€ plus the extra money earned in the task.</p></sec><sec id="s4-3"><title>Genotypic analysis</title><p>Peripheral blood was collected by lancet and stored on Whatman FTA micro cards (Sigma-Aldrich). DNA was extracted using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). The VNTR polymorphism in the <italic>DAT1</italic> gene was investigated by PCR with 5’-fluorescent-dye-labeled forward primer and automated detection of PCR products by capillary electrophoresis (details of the procedure provided in the supplement). The single base primer extension (SBE) method also known as SNaPshot minisequencing was applied for the typing of single nucleotide polymorphism (SNP) variants (details provided in supplement). Accordingly, five informative SNPs [<italic>DRD2/ANKK1 Taq1A</italic> (<italic>rs1800497</italic>), <italic>BDNF</italic> (<italic>rs6265</italic>), <italic>CDH13</italic> (<italic>rs3784943</italic>), <italic>OPRM1</italic> (<italic>rs1799971</italic>) and PPP1R1B/DARPP-32 (<italic>rs907094</italic>)] were analysed simultaneously applying a multiplex strategy for PCR and SNaPshot minisequencing of purified PCR products. Typing of Val158Met variants (<italic>rs4680</italic>) in the <italic>COMT</italic> gene was carried out separately, applying a singleplex approach for PCR and SNaPshot. The <italic>OPRM1</italic> and <italic>BDNF</italic> SNPs were not included in the analysis in this task. Genetic data from three participants were lost. This led to the group distributions depicted in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1k</xref>. For details on the analysis see Supplementary Note 2.</p></sec><sec id="s4-4"><title>Task design</title><p>In the task, participants made an initial choice at stage one which took them to one of the two possible states (‘planets’) in stage two. There were two possible states in the first stage, each featuring a pair of spaceships. Each of the spaceships flew deterministically to one of the two planets where they encountered an alien who gave them either positive or negative points. The points in each planet changed according to a Gaussian random walk in the interval [–4, 5], rounded to whole numbers. Importantly, since both first-stage states led to the same two possible second-stage states, participants could transfer knowledge from the pair of spaceships in one first-stage state to the pair in the other. According to the conventional definition adopted here, a completely model-free agent relies entirely on its direct experience and will choose a spaceship based only on its reward history in previous trials featuring the same first-stage state, regardless of their experience with the other pair of spaceships. A completely model-based agent however will use the causal structure of the task to update the value of the spaceships based on which planet they fly to. This means that knowing that spaceship A and C fly to the same planet (but appear in different first step states) enables the model-based agent to learn about spaceship C by experiencing the outcome of its choice of spaceship A.</p><p>Participants had 2000 ms to choose in the first step and then again 2000ms to press the space bar once they had encountered the alien. Each acquired point was translated to 4 Eurocents and added to the overall compensation of the participant at the end of the experiment. The story and a thorough training session were employed to increase the comprehension of the task, as done before (<xref ref-type="bibr" rid="bib16">Decker et al., 2016</xref>). To avoid all participants behaving in a model-based way (<xref ref-type="bibr" rid="bib30">Feher da Silva and Hare, 2020</xref>) we increased the difficulty of the task by dynamically changing the drift of the reward-determining Gaussian walks. The Gaussian random walks, therefore, had various drift rates (0.5, 1, and 2). We generated one trajectory and shuffled it around to create two different testing sessions of similar difficulty. Each participant first went through an automated rigorous explanation of the task followed by 25 practice trials before completing 200 trials of the task.</p></sec><sec id="s4-5"><title>Behavioural analysis</title><p>To regularize our inference, we used a hierarchical Bayesian approach in all our analyses. We report estimates in parameter estimation space and indicate the precision of our estimates with credible intervals (<xref ref-type="bibr" rid="bib110">Zhang et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Kruschke, 2014</xref>). We also report the proportion of the credible interval that is above or below zero. Model-agnostic analysis of behaviour focused on predicting the probability of staying with the previous choice (choose the spaceship that flies to the same planet as in the previous trial). Behaviour was analysed using the <italic>brms</italic> package in R (<xref ref-type="bibr" rid="bib9">Bürkner, 2017</xref>) which employs the probabilistic programming language Stan (<xref ref-type="bibr" rid="bib10">Carpenter, 2017</xref>). We fit a binomial model that predicted staying with the previous choice from reward obtained in the previous trial, modulated by the previous state (same or different), drug treatment, and session. The effects of session, previous state, previous points and all interactions between them were drawn from a multivariate normal distribution (were considered as correlated random effects). We report 95% credible intervals of estimates on the log-odds scale. Parameters were estimated with 4 chains, every 3000 iterations (1000 warmup), with priors listed in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Prior distributions for the behavioural analysis.</title></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="bottom"><bold>Standard deviations</bold></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf77"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mo>∼</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom"><bold>Regression coefficients</bold></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf78"><mml:mi>β</mml:mi><mml:mo>~</mml:mo><mml:mi> </mml:mi><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mn>0,3</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom"><bold>Intercept</bold></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf79"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>S</mml:mi><mml:mi>t</mml:mi><mml:mi>u</mml:mi><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo>(</mml:mo><mml:mn>3,0</mml:mn><mml:mo>,</mml:mo><mml:mn>10</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula></td></tr><tr><td align="left" valign="bottom"><bold>Prior for the correlation matrix</bold></td><td align="left" valign="bottom"><inline-formula><mml:math id="inf80"><mml:mi>R</mml:mi><mml:mo>~</mml:mo><mml:mi>L</mml:mi><mml:mi>K</mml:mi><mml:mi>J</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula></td></tr></tbody></table></table-wrap><p>The number of participants used in the analysis depends on whether both sessions were included and whether genetic data were used (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1l</xref> for an overview). Analysis with amisulpride blood serum levels included a categorial variable for the serum. A categorical variable was chosen due to the skewed distribution of serum levels. To relate behaviour to the parameters of the computational model we extracted the random slopes for each participant for the second session for both the effects of previous points on staying behaviour in trials with the same first stage state as in the previous trial, as well as the random slopes for the different vs same first state trials. We then standardized all slopes and the computational parameters and used two separate linear models to predict both slopes from the three computational parameters.</p></sec><sec id="s4-6"><title>Computational models</title><p>We defined three computational models that define the subjective values <inline-formula><mml:math id="inf81"><mml:mi>Q</mml:mi></mml:math></inline-formula> of participants’ action <inline-formula><mml:math id="inf82"><mml:mi>a</mml:mi></mml:math></inline-formula>, in trial <inline-formula><mml:math id="inf83"><mml:mi>t</mml:mi></mml:math></inline-formula>, with a first stage state <inline-formula><mml:math id="inf84"><mml:mi>s</mml:mi></mml:math></inline-formula>, as the weighted average of model-based (<inline-formula><mml:math id="inf85"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>) and model-free (<inline-formula><mml:math id="inf86"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>) subjective values.<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mi>Q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mi>ω</mml:mi><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf87"><mml:mi>ω</mml:mi></mml:math></inline-formula> is the weighting parameter (larger influence on choice of model-based values is indicated by <inline-formula><mml:math id="inf88"><mml:mi>ω</mml:mi></mml:math></inline-formula> being close to 1 and model-free control by <inline-formula><mml:math id="inf89"><mml:mi>ω</mml:mi></mml:math></inline-formula> being close to 0). The subjective values are then mapped on to probability of choosing <inline-formula><mml:math id="inf90"><mml:mi>a</mml:mi></mml:math></inline-formula>, and not <inline-formula><mml:math id="inf91"><mml:mi>a</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula>, with the soft-max transformation:<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>η</mml:mi><mml:mo>∗</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>η</mml:mi><mml:mo>∗</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>η</mml:mi><mml:mo>∗</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>a</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf92"><mml:mi>η</mml:mi></mml:math></inline-formula> is the <italic>inverse temperature</italic> parameter, that determines the stochasticity of choices and the exploration-exploitation trade-off. In the models that include stickiness parameters, the value function for action <inline-formula><mml:math id="inf93"><mml:mi>a</mml:mi></mml:math></inline-formula> was extended as follows:<disp-formula id="equ3"><mml:math id="m3"><mml:mrow><mml:mi>Q</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mi>ω</mml:mi><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>ω</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:mo>∗</mml:mo><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>π</mml:mi><mml:mo>∗</mml:mo><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where the indicator functions were defined as being 1 for the action that was the same as in the previous trial (<inline-formula><mml:math id="inf94"><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>) or the stimulus that was chosen in the previous trial (<inline-formula><mml:math id="inf95"><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>). The <inline-formula><mml:math id="inf96"><mml:mi>ρ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf97"><mml:mi>π</mml:mi></mml:math></inline-formula> parameters, therefore, determine the degree to which previous actions (or stimuli) tended to be repeated (<xref ref-type="bibr" rid="bib45">Kool et al., 2016</xref>).</p></sec><sec id="s4-7"><title>Deterministic learning model (M1)</title><p>Because the outcomes at the second stage are determined by Gaussian random walks, the objectively best prediction by the agent is the last encountered outcome. We defined a model (M1), where the model-free subjective value of each of the spaceships is the last encountered outcome following the choice of that spaceship, and the model-based subjective value of each spaceship is the subjective value of the last encountered outcome following the planet that this spaceship flies to. This means that the update equation of the model-free agent after receiving outcome <inline-formula><mml:math id="inf98"><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> following an action <inline-formula><mml:math id="inf99"><mml:mi>a</mml:mi></mml:math></inline-formula>, in trial <inline-formula><mml:math id="inf100"><mml:mi>t</mml:mi></mml:math></inline-formula>, with first state <inline-formula><mml:math id="inf101"><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , is defined as<disp-formula id="equ4"><mml:math id="m4"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>.</mml:mo></mml:math></disp-formula></p><p>In the same trial, the value of the for the unchosen actions across both first level states are shrunk towards 0 with forgetting parameter <inline-formula><mml:math id="inf102"><mml:mi>γ</mml:mi><mml:mi> </mml:mi><mml:mo>∈</mml:mo><mml:mo>[</mml:mo><mml:mn>0,1</mml:mn><mml:mo>]</mml:mo></mml:math></inline-formula>:<disp-formula id="equ5"><mml:math id="m5"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>γ</mml:mi></mml:mrow></mml:mfenced><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ6"><mml:math id="m6"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">`</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>γ</mml:mi></mml:mrow></mml:mfenced><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ7"><mml:math id="m7"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>γ</mml:mi></mml:mrow></mml:mfenced><mml:mi mathvariant="normal"> </mml:mi><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf103"><mml:msup><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> is the unchosen action and <inline-formula><mml:math id="inf104"><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi>`</mml:mi></mml:math></inline-formula> is the unencountered state. The model-based agent, on the other hand, after receiving outcome <inline-formula><mml:math id="inf105"><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> following an action <inline-formula><mml:math id="inf106"><mml:mi>a</mml:mi></mml:math></inline-formula>, in trial <inline-formula><mml:math id="inf107"><mml:mi>t</mml:mi></mml:math></inline-formula>, with first state <inline-formula><mml:math id="inf108"><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , updates not only the experienced first stage state but also the unencountered first stage which would have led to the same outcome:<disp-formula id="equ8"><mml:math id="m8"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula><disp-formula id="equ9"><mml:math id="m9"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mi>`</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>where, <inline-formula><mml:math id="inf109"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the subjective value of the second stage state that action <inline-formula><mml:math id="inf110"><mml:mi>a</mml:mi></mml:math></inline-formula> deterministically leads to.</p></sec><sec id="s4-8"><title>Dual-system reinforcement learning models (M2 and M3)</title><p>We compared our model M1 to two versions of a dual-system reinforcement learning model inspired by <xref ref-type="bibr" rid="bib46">Kool et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Kool et al., 2016</xref>. In these models, the model-free agent learns the subjective values of spaceships and planets through a temporal difference-learning algorithm (<xref ref-type="bibr" rid="bib14">Daw et al., 2011</xref>; <xref ref-type="bibr" rid="bib89">Sutton and Barto, 1998</xref>). The model-free agent was defined by 3 free parameters: the learning rate at the first stage (<inline-formula><mml:math id="inf111"><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>), and the second stage (<inline-formula><mml:math id="inf112"><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>), where the eligibility trace (<inline-formula><mml:math id="inf113"><mml:mi>λ</mml:mi></mml:math></inline-formula>) determines the degree to which the outcome at the second stage retrospectively transfers to the first stage. In simple terms, the model increases (or decreases) the subjective value of an action at stage 1 proportionally to how positively (or negatively) surprising the outcome was, but discounted by the learning rate that describes the contributions of previous outcomes of that specific action. Conversely, the model-based agent is aware of the structure of the task. Specifically, in trial <inline-formula><mml:math id="inf114"><mml:mi>t</mml:mi></mml:math></inline-formula>, with first stage state <inline-formula><mml:math id="inf115"><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, we define the model-free subjective value of action <inline-formula><mml:math id="inf116"><mml:mi>a</mml:mi></mml:math></inline-formula> as<disp-formula id="equ10"><mml:math id="m10"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula><disp-formula id="equ11"><mml:math id="m11"><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>and the model-based subjective values of action <inline-formula><mml:math id="inf117"><mml:mi>a</mml:mi></mml:math></inline-formula> as<disp-formula id="equ12"><mml:math id="m12"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:mfenced><mml:mi>*</mml:mi><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf118"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the subjective value of the second stage <inline-formula><mml:math id="inf119"><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> at time <inline-formula><mml:math id="inf120"><mml:mi>t</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf121"><mml:mi>T</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>a</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> is the transition matrix from first to second stage states. The agents learn the values of the planets, <inline-formula><mml:math id="inf122"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , by<disp-formula id="equ13"><mml:math id="m13"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula><disp-formula id="equ14"><mml:math id="m14"><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></disp-formula><disp-formula id="equ15"><mml:math id="m15"><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mi>F</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>a</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula></p><p>The learning rates at the two stages were either different (M2), or the same (M3).</p></sec><sec id="s4-9"><title>Model estimation</title><p>We estimated the model parameters for both sessions in one hierarchical (multilevel) Bayesian model. This approach pools information across different levels (drug groups, and participants) and thus leads to more stable individual parameter estimates (<xref ref-type="bibr" rid="bib3">Ahn et al., 2017</xref>), reduces overfitting (<xref ref-type="bibr" rid="bib59">McElreath, 2016</xref>), and enables us to estimate in one model both individual and group level parameters as well as differences between sessions (<xref ref-type="bibr" rid="bib56">Lengersdorff et al., 2020</xref>). Models were implemented in Stan (<xref ref-type="bibr" rid="bib10">Carpenter, 2017</xref>) using R as the interface. Stan uses a Markov Chain Monte Carlo sampling method to describe posterior distributions of model parameters. We ran each candidate model with four independent chains and 3000 iterations (1000 warm-up). Convergence of sampling chains was estimated through the Gelman-Rubin <inline-formula><mml:math id="inf123"><mml:mover accent="true"><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> statistic (<xref ref-type="bibr" rid="bib37">Gelman and Rubin, 1992</xref>), whereby we considered <inline-formula><mml:math id="inf124"><mml:mover accent="true"><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> values smaller than 1.01 as acceptable.</p><p>For all subject level parameters (e.g., <inline-formula><mml:math id="inf125"><mml:mi>ω</mml:mi></mml:math></inline-formula>) we drew both the baseline (<inline-formula><mml:math id="inf126"><mml:msub><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>) and the session difference (<inline-formula><mml:math id="inf127"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>ω</mml:mi></mml:math></inline-formula>), from a multivariate Gaussian prior. Specifically, for model M1:<disp-formula id="equ16"><mml:math id="m16"><mml:mfenced separators="|"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">ω</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>Δ</mml:mi><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">η</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced><mml:mo>~</mml:mo><mml:mi>M</mml:mi><mml:mi>V</mml:mi><mml:mi>N</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mi> </mml:mi><mml:mi> </mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">ω</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">η</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf128"><mml:mi>S</mml:mi></mml:math></inline-formula> is the covariance matrix, which was factored into a diagonal matrix with standard deviations and the correlation matrix <inline-formula><mml:math id="inf129"><mml:mi>R</mml:mi></mml:math></inline-formula> (<xref ref-type="bibr" rid="bib9">Bürkner, 2017</xref>; <xref ref-type="bibr" rid="bib59">McElreath, 2016</xref>). The prime denotes the parameters in estimation space. The parameters that were fully constrained (i.e., <inline-formula><mml:math id="inf130"><mml:mi>ω</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="inf131"><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , <inline-formula><mml:math id="inf132"><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> , <inline-formula><mml:math id="inf133"><mml:mi>λ</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="inf134"><mml:mi>γ</mml:mi></mml:math></inline-formula>) were estimated in the inverse probit space and the parameters that only had a lower bound (i.e., <inline-formula><mml:math id="inf135"><mml:mi>η</mml:mi></mml:math></inline-formula>) were estimated in log space. The hyper-priors for all group-level means were weakly informative, <inline-formula><mml:math id="inf136"><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi> </mml:mi><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mn>0,1</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula>, the prior for group-level standard deviations were <inline-formula><mml:math id="inf137"><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>H</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>f</mml:mi><mml:mi>N</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>0,1</mml:mn></mml:mrow></mml:mfenced></mml:math></inline-formula> , and the prior for the correlation matrix was <inline-formula><mml:math id="inf138"><mml:mi>R</mml:mi><mml:mo>~</mml:mo><mml:mi>L</mml:mi><mml:mi>K</mml:mi><mml:mi>J</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula>. The parameters in the second session were therefore defined by their estimated baseline and difference between the sessions. For instance, the model-based weight <inline-formula><mml:math id="inf139"><mml:mi>ω</mml:mi></mml:math></inline-formula> in the second session for participant <inline-formula><mml:math id="inf140"><mml:mi>i</mml:mi></mml:math></inline-formula> was defined as:<disp-formula id="equ17"><mml:math id="m17"><mml:mi>ω</mml:mi><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo><mml:mo>)</mml:mo></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf141"><mml:mi>ϕ</mml:mi></mml:math></inline-formula> is the cumulative distribution function of the standard normal distribution (inverse of probit). Effect sizes are calculated by normalizing the relevant regression coefficients by the pooled standard deviation (square root of the sum of all relevant variance components <xref ref-type="bibr" rid="bib68">Nalborczyk et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Hedges, 2007</xref>). In models where there are no random effects, this reduces to a Cohen’s d. For example, the effect sizes for drug effects on <inline-formula><mml:math id="inf142"><mml:mi>ω</mml:mi></mml:math></inline-formula> were calculated by dividing the estimated difference between group means by the square root of the sum of the variance of both the baseline (<inline-formula><mml:math id="inf143"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula>) and the session difference (<inline-formula><mml:math id="inf144"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula>). We used the same procedure in all computational models.</p></sec><sec id="s4-10"><title>Model comparison and validation</title><p>We used the trial-based Leave-One-Out Information Criterion (LOOIC) to compare the three models using the loo package in R (<xref ref-type="bibr" rid="bib95">Vehtari et al., 2017</xref>). The LOOIC estimates out-of-sample predictive accuracy of each trial and is more informative than simpler point-estimate information criterions used commonly (such as the Akaike information criterion). Lower LOOIC scores indicate better prediction accuracy out of sample. Additionally, we compared models with bootstrapped pseudo Bayesian Model Average relative weights of the models that reflect the posterior probability of each model given the data (<xref ref-type="bibr" rid="bib108">Yao et al., 2018</xref>). To validate the novel model M1, we first used the posterior means of the estimated parameters to simulate behaviour in both sessions. To see how well we can retrieve the model parameters we reran the parameter estimation on the simulated behaviour with the same model (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1 and d</xref>). We also ran the same analysis of staying behaviour on this synthetic dataset and reproduced the behavioural plots from <xref ref-type="fig" rid="fig3">Figure 3</xref> (compare to <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1 and e</xref>). We used the same logistic hierarchical Bayesian model to statistically evaluate the crucial aspects of the behavioural analysis (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1 and e</xref>, compare to <xref ref-type="fig" rid="fig3">Figure 3c</xref>). To get the posterior predictive accuracy of the model we predicted the choice on each trial for each participant for 8000 samples drawn from the posterior distribution and then calculated the average accuracy for each participant.</p></sec><sec id="s4-11"><title>Estimation of the effects of the pharmacological treatment</title><p>To statistically evaluate the effect of our treatment on all the parameters in the model, we included two regression terms when defining the group-level means of the difference between sessions:<disp-formula id="equ18"><mml:math id="m18"><mml:mfenced separators="|"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">ω</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>Δ</mml:mi><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:mi>Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">η</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced><mml:mo>~</mml:mo><mml:mi>M</mml:mi><mml:mi>V</mml:mi><mml:mi>N</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mi> </mml:mi><mml:mi> </mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">ω</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:msubsup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:msubsup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msubsup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msubsup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:maligngroup/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">η</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">`</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:msubsup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:msubsup><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf145"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf146"><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>*</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> are coefficients drawn from prior distribution <inline-formula><mml:math id="inf147"><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mn>0,1.5</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula> and <inline-formula><mml:math id="inf148"><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf149"><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> are dummy variables for the two drugs. To see which of the parameters are affected by the drug treatment, we included group-level effects on all parameters. This model was extended in the second step to include a group-level categorical variable for high/low serum levels of amisulpride (coded as 1 for high serum level and 0 otherwise). In the third step, the model also included the subject-level stickiness parameters and all corresponding group level effects.</p><p>To estimate the effects of mood, working memory performance, sex, weight and age, we ran another model predicting estimated differences in <inline-formula><mml:math id="inf150"><mml:mi>ω</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="inf151"><mml:mi>η</mml:mi></mml:math></inline-formula> across sessions from those variables. Similarly, in another model, the session differences were predicted by drug variables and their interactions with the four genotype variables. Full model definitions and outputs are provided in supplementary material.</p></sec><sec id="s4-12"><title>Reading span task</title><p>We used an automated version of the Reading Span Task, where in each block participants saw 2–6 words serially presented that they had to recall by the end of the trial in any order. The words were interlaced with sentences that participants were instructed to judge as either making sense or not (<xref ref-type="bibr" rid="bib43">Klaus and Schriefers, 2016</xref>). Participants played 15 blocks. Correctly recalled items were calculated as a proportion within the block and then averaged across blocks. The effect of the drug treatment was calculated with a Bayesian linear model where the mean score was predicted by drug treatment.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Supervision, Investigation, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Supervision, Investigation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Supervision, Investigation, Project administration</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Supervision, Investigation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Funding acquisition</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Software, Supervision, Methodology, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Experiments were conducted at the Medical University of Vienna and the study was approved by the Ethical Committee of the Medical University of Vienna (EK N. 1393/2017). Informed consent was provided by all research participants.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary Data and Model Summaries.</title><p>(a) Estimates and CIs of fixed effects of the Bayesian logistic regression predicting staying behaviour. Q2.5 and Q97.5 are the 2.5% and 97.5% quantiles of the posterior parameter distribution. For details on how the posterior distributions were calculated refer to the code online (Ami = Amisulpride, Nal = Naltrexone).(b) Results of a Bayesian logistic linear model predicting percentage correct from drug groups.(c) Mood in mean and standard deviation at time of pill intake (T1) and 3 hr later (T2).(d) Drug effects on differences in positive PANAS scales (centralized) between sessions. Drug variables coded as follows: nal is as dummy variable for naltrexone (1 for naltrexone, 0 otherwise), ami is a dummy variable for amisulpride, and serum_ami is a dummy variable for serum (1 only in the high serum group, and 0 otherwise). (e) Drug effects on differences in negative PANAS scales (centralized) between sessions. Drug variables coded as before. (f) Drug effects on session differences in <inline-formula><mml:math id="inf152"><mml:mi>ω</mml:mi></mml:math></inline-formula>, including mood at baseline, difference in mood from baseline and working memory performance as covariates, as well as sex, age and weight as moderators of effects. Drug variables coded as before, all other dependent variables scaled and centralized. (g) Drug effects on session differences in <inline-formula><mml:math id="inf153"><mml:mi>η</mml:mi></mml:math></inline-formula>, including mood at baseline, difference in mood from baseline and working memory performance as covariates, as well as sex, age and weight as moderators of effects. Drug variables coded as before, all other dependent variables scaled and centralized. (h) Drug effects on session differences in <inline-formula><mml:math id="inf154"><mml:mi>ω</mml:mi></mml:math></inline-formula>, from genetic variables. Drug variables coded as before, all other dependent variables scaled and centralized. (i) Drug effects on session differences in <inline-formula><mml:math id="inf155"><mml:mi>ω</mml:mi></mml:math></inline-formula>, from genetic variables. Drug variables coded as before, all other dependent variables scaled and centralized. (j) Description of participants in terms of body mass index (BMI), age and sex with mean (m) and standard deviation (sd). (k) Distribution of genotypes. (l) Number of participants per drug group used in analysis.</p></caption><media xlink:href="elife-79661-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-79661-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The data and the analysis scripts are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/nacemikus/mbmf-da-op.git">https://github.com/nacemikus/mbmf-da-op.git</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:47f15ecdba3571787c7da237ce64f09a3a6afef6;origin=https://github.com/nacemikus/mbmf-da-op;visit=swh:1:snp:9490c0a2d0cad62b71a32f2a692ec91b8fb3626b;anchor=swh:1:rev:4822b12aa33d8e5eb60d8ad5af2a0d3392e00e20">swh:1:rev:4822b12aa33d8e5eb60d8ad5af2a0d3392e00e20</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Mikus</surname><given-names>N</given-names></name><name><surname>Korb</surname><given-names>S</given-names></name><name><surname>Massaccesi</surname><given-names>C</given-names></name><name><surname>Gausterer</surname><given-names>C</given-names></name><name><surname>Graf</surname><given-names>I</given-names></name><name><surname>Willeit</surname><given-names>M</given-names></name><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Lamm</surname><given-names>C</given-names></name><name><surname>Silani</surname><given-names>G</given-names></name><name><surname>Mathys</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Making data and code from the article &quot;Effects of dopamine D2 and opioid receptor antagonism on the trade-off between model-based and model-free behaviour in healthy volunteers&quot; available online.</data-title><source>Zenodo</source><pub-id pub-id-type="doi">10.5281/zenodo.7221355</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The study was supported by the Vienna Science and Technology Fund (WWTF) with a grant (CS15- 003) awarded to Giorgia Silani and Christoph Eisenegger and a grant (VRG13-007) awarded to Christoph Eisenegger and Claus Lamm. We thank Prof. Boris Quednow for his advice on the study design. This work would not be possible were it not for the students who have carried out the data collection: Mani Erfanian Abdoust, Anne Franziska Braun, Raimund Bühler, Lena Drost, Manuel Czornik, Lisa Hollerith, Berit Hansen, Luise Huybrechts, Merit Pruin, Vera Ritter, Frederic Schwetz, Conrad Seewald, Carolin Waleew, Luca Wiltgen, Stephan Zillmer. We thank Catherine Hartley for sending us her version of the task implemented in matlab, and for allowing us to use the stimuli. We are grateful to Wouter Kool for making his version of the task implemented in JsPsych freely available on github. We also thank Lei Zhang and Lukas Lengersdorff for helpful discussions on the statistical procedures used in the manuscript. The manuscript has significantly improved from the constructive and insightful remarks of the three reviewers.</p><p>Open access funding provided by University of Vienna.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>RA</given-names></name><name><surname>Moutoussis</surname><given-names>M</given-names></name><name><surname>Nour</surname><given-names>MM</given-names></name><name><surname>Dahoun</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>D</given-names></name><name><surname>Illingworth</surname><given-names>B</given-names></name><name><surname>Veronese</surname><given-names>M</given-names></name><name><surname>Mathys</surname><given-names>C</given-names></name><name><surname>de Boer</surname><given-names>L</given-names></name><name><surname>Guitart-Masip</surname><given-names>M</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Howes</surname><given-names>OD</given-names></name><name><surname>Roiser</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Variability in action selection relates to striatal dopamine 2/3 receptor availability in humans: a PET neuroimaging study using reinforcement learning and active inference models</article-title><source>Cerebral Cortex</source><volume>30</volume><fpage>3573</fpage><lpage>3589</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhz327</pub-id><pub-id pub-id-type="pmid">32083297</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agmo</surname><given-names>A</given-names></name><name><surname>Galvan</surname><given-names>A</given-names></name><name><surname>Talamantes</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Reward and reinforcement produced by drinking sucrose: two processes that may depend on different neurotransmitters</article-title><source>Pharmacology, Biochemistry, and Behavior</source><volume>52</volume><fpage>403</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(95)00128-j</pub-id><pub-id pub-id-type="pmid">8577808</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>WY</given-names></name><name><surname>Haines</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Revealing neurocomputational mechanisms of reinforcement learning and decision-making with the hbayesdm package</article-title><source>Computational Psychiatry</source><volume>1</volume><fpage>24</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1162/CPSY_a_00002</pub-id><pub-id pub-id-type="pmid">29601060</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AFT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Catecholamine influences on dorsolateral prefrontal cortical networks</article-title><source>Biological Psychiatry</source><volume>69</volume><fpage>e89</fpage><lpage>e99</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.01.027</pub-id><pub-id pub-id-type="pmid">21489408</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balleine</surname><given-names>BW</given-names></name><name><surname>O’Doherty</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action</article-title><source>Neuropsychopharmacology</source><volume>35</volume><fpage>48</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/npp.2009.131</pub-id><pub-id pub-id-type="pmid">19776734</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Grecksch</surname><given-names>G</given-names></name><name><surname>Kraus</surname><given-names>J</given-names></name><name><surname>Loh</surname><given-names>HH</given-names></name><name><surname>Schroeder</surname><given-names>H</given-names></name><name><surname>Höllt</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice</article-title><source>Naunyn-Schmiedeberg’s Archives of Pharmacology</source><volume>365</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1007/s00210-002-0533-2</pub-id><pub-id pub-id-type="pmid">11919654</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>D</given-names></name><name><surname>Grant</surname><given-names>ER</given-names></name><name><surname>Pohorecky</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats</article-title><source>Brain Research</source><volume>621</volume><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(93)90309-b</pub-id><pub-id pub-id-type="pmid">7693299</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brozoski</surname><given-names>TJ</given-names></name><name><surname>Brown</surname><given-names>RM</given-names></name><name><surname>Rosvold</surname><given-names>HE</given-names></name><name><surname>Goldman</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey</article-title><source>Science</source><volume>205</volume><fpage>929</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1126/science.112679</pub-id><pub-id pub-id-type="pmid">112679</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bürkner</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Brms: an R package for bayesian multilevel models using stan</article-title><source>Journal of Statistical Software</source><volume>8</volume><elocation-id>i01</elocation-id><pub-id pub-id-type="doi">10.18637/jss.v080.i01</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Stan: A probabilistic programming language</article-title><source>Journal of Statistical Software</source><volume>10</volume><elocation-id>i01</elocation-id><pub-id pub-id-type="doi">10.18637/jss.v076.i01</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The costs and benefits of brain dopamine for cognitive control</article-title><source>Wiley Interdisciplinary Reviews. Cognitive Science</source><volume>7</volume><fpage>317</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1002/wcs.1401</pub-id><pub-id pub-id-type="pmid">27507774</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chemistry of the adaptive mind: lessons from dopamine</article-title><source>Neuron</source><volume>104</volume><fpage>113</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.09.035</pub-id><pub-id pub-id-type="pmid">31600509</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daw</surname><given-names>ND</given-names></name><name><surname>Niv</surname><given-names>Y</given-names></name><name><surname>Dayan</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Uncertainty-based competition between prefrontal and dorsolateral striatal systems for behavioral control</article-title><source>Nature Neuroscience</source><volume>8</volume><fpage>1704</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1038/nn1560</pub-id><pub-id pub-id-type="pmid">16286932</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daw</surname><given-names>ND</given-names></name><name><surname>Gershman</surname><given-names>SJ</given-names></name><name><surname>Seymour</surname><given-names>B</given-names></name><name><surname>Dayan</surname><given-names>P</given-names></name><name><surname>Dolan</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Model-Based influences on humans’ choices and striatal prediction errors</article-title><source>Neuron</source><volume>69</volume><fpage>1204</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.02.027</pub-id><pub-id pub-id-type="pmid">21435563</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daw</surname><given-names>ND</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Are we of two minds?</article-title><source>Nature Neuroscience</source><volume>21</volume><fpage>1497</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1038/s41593-018-0258-2</pub-id><pub-id pub-id-type="pmid">30349102</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decker</surname><given-names>JH</given-names></name><name><surname>Otto</surname><given-names>AR</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name><name><surname>Hartley</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From creatures of habit to goal-directed learners: tracking the developmental emergence of model-based reinforcement learning</article-title><source>Psychological Science</source><volume>27</volume><fpage>848</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1177/0956797616639301</pub-id><pub-id pub-id-type="pmid">27084852</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeCoster</surname><given-names>J</given-names></name><name><surname>Gallucci</surname><given-names>M</given-names></name><name><surname>Iselin</surname><given-names>AMR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Best practices for using median splits, artificial categorization, and their continuous alternatives</article-title><source>Journal of Experimental Psychopathology</source><volume>2</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.5127/jep.008310</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delamater</surname><given-names>AR</given-names></name><name><surname>Sclafani</surname><given-names>A</given-names></name><name><surname>Bodnar</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Pharmacology of sucrose-reinforced place-preference conditioning: effects of naltrexone</article-title><source>Pharmacology, Biochemistry, and Behavior</source><volume>65</volume><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/s0091-3057(99)00251-8</pub-id><pub-id pub-id-type="pmid">10764925</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deserno</surname><given-names>L</given-names></name><name><surname>Huys</surname><given-names>QJM</given-names></name><name><surname>Boehme</surname><given-names>R</given-names></name><name><surname>Buchert</surname><given-names>R</given-names></name><name><surname>Heinze</surname><given-names>HJ</given-names></name><name><surname>Grace</surname><given-names>AA</given-names></name><name><surname>Dolan</surname><given-names>RJ</given-names></name><name><surname>Heinz</surname><given-names>A</given-names></name><name><surname>Schlagenhauf</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ventral striatal dopamine reflects behavioral and neural signatures of model-based control during sequential decision making</article-title><source>PNAS</source><volume>112</volume><fpage>1595</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1073/pnas.1417219112</pub-id><pub-id pub-id-type="pmid">25605941</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Chiara</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Drug addiction as dopamine-dependent associative learning disorder</article-title><source>European Journal of Pharmacology</source><volume>375</volume><fpage>13</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/s0014-2999(99)00372-6</pub-id><pub-id pub-id-type="pmid">10443561</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dickinson</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1985">1985</year><source>The Development of Behavioural Autonomy</source><publisher-name>Philos. Trans. R. Soc.London Ser. B</publisher-name></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodds</surname><given-names>CM</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Dove</surname><given-names>A</given-names></name><name><surname>Regenthal</surname><given-names>R</given-names></name><name><surname>Baumann</surname><given-names>F</given-names></name><name><surname>Bullmore</surname><given-names>E</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory</article-title><source>Psychopharmacology</source><volume>207</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s00213-009-1634-0</pub-id><pub-id pub-id-type="pmid">19672580</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolan</surname><given-names>RJ</given-names></name><name><surname>Dayan</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Goals and habits in the brain</article-title><source>Neuron</source><volume>80</volume><fpage>312</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.09.007</pub-id><pub-id pub-id-type="pmid">24139036</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doll</surname><given-names>BB</given-names></name><name><surname>Bath</surname><given-names>KG</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name><name><surname>Frank</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Variability in dopamine genes dissociates model-based and model-free reinforcement learning</article-title><source>The Journal of Neuroscience</source><volume>36</volume><fpage>1211</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1901-15.2016</pub-id><pub-id pub-id-type="pmid">26818509</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durstewitz</surname><given-names>D</given-names></name><name><surname>Seamans</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-O-methyltransferase genotypes and schizophrenia</article-title><source>Biological Psychiatry</source><volume>64</volume><fpage>739</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2008.05.015</pub-id><pub-id pub-id-type="pmid">18620336</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Pedroni</surname><given-names>A</given-names></name><name><surname>Rieskamp</surname><given-names>J</given-names></name><name><surname>Zehnder</surname><given-names>C</given-names></name><name><surname>Ebstein</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>E</given-names></name><name><surname>Knoch</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dat1 polymorphism determines L-dopa effects on learning about others’ prosociality</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e67820</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0067820</pub-id><pub-id pub-id-type="pmid">23861813</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Naef</surname><given-names>M</given-names></name><name><surname>Linssen</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Gandamaneni</surname><given-names>PK</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Role of dopamine D2 receptors in human reinforcement learning</article-title><source>Neuropsychopharmacology</source><volume>39</volume><fpage>2366</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1038/npp.2014.84</pub-id><pub-id pub-id-type="pmid">24713613</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="software"><person-group person-group-type="author"><collab>EMCDDA</collab></person-group><year iso-8601-date="2020">2020</year><data-title>European drug report 2020: trends and developments</data-title><source>EMCDDA</source></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everitt</surname><given-names>BJ</given-names></name><name><surname>Belin</surname><given-names>D</given-names></name><name><surname>Economidou</surname><given-names>D</given-names></name><name><surname>Pelloux</surname><given-names>Y</given-names></name><name><surname>Dalley</surname><given-names>JW</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Review. Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>363</volume><fpage>3125</fpage><lpage>3135</lpage><pub-id pub-id-type="doi">10.1098/rstb.2008.0089</pub-id><pub-id pub-id-type="pmid">18640910</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feher da Silva</surname><given-names>C</given-names></name><name><surname>Hare</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Humans primarily use model-based inference in the two-stage task</article-title><source>Nature Human Behaviour</source><volume>4</volume><fpage>1053</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1038/s41562-020-0905-y</pub-id><pub-id pub-id-type="pmid">32632333</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>File</surname><given-names>SE</given-names></name><name><surname>Silverstone</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Naloxone changes self-ratings but not performance in normal subjects</article-title><source>Psychopharmacology</source><volume>74</volume><fpage>353</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1007/BF00432746</pub-id><pub-id pub-id-type="pmid">6794081</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The role of D2-autoreceptors in regulating dopamine neuron activity and transmission</article-title><source>Neuroscience</source><volume>282</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2014.01.025</pub-id><pub-id pub-id-type="pmid">24463000</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MJ</given-names></name><name><surname>Seeberger</surname><given-names>LC</given-names></name><name><surname>O’reilly</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>By carrot or by stick: cognitive reinforcement learning in parkinsonism</article-title><source>Science</source><volume>306</volume><fpage>1940</fpage><lpage>1943</lpage><pub-id pub-id-type="doi">10.1126/science.1102941</pub-id><pub-id pub-id-type="pmid">15528409</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated parkinsonism</article-title><source>Journal of Cognitive Neuroscience</source><volume>17</volume><fpage>51</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1162/0898929052880093</pub-id><pub-id pub-id-type="pmid">15701239</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MJ</given-names></name><name><surname>O’Reilly</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol</article-title><source>Behavioral Neuroscience</source><volume>120</volume><fpage>497</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1037/0735-7044.120.3.497</pub-id><pub-id pub-id-type="pmid">16768602</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>MJ</given-names></name><name><surname>Doll</surname><given-names>BB</given-names></name><name><surname>Oas-Terpstra</surname><given-names>J</given-names></name><name><surname>Moreno</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Prefrontal and striatal dopaminergic genes predict individual differences in exploration and exploitation</article-title><source>Nature Neuroscience</source><volume>12</volume><fpage>1062</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1038/nn.2342</pub-id><pub-id pub-id-type="pmid">19620978</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelman</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Inference from iterative simulation using multiple sequences</article-title><source>Statistical Science</source><volume>7</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.1214/ss/1177011136</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershman</surname><given-names>SJ</given-names></name><name><surname>Uchida</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Believing in dopamine</article-title><source>Nature Reviews. Neuroscience</source><volume>20</volume><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1038/s41583-019-0220-7</pub-id><pub-id pub-id-type="pmid">31570826</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillan</surname><given-names>CM</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Whelan</surname><given-names>R</given-names></name><name><surname>Phelps</surname><given-names>EA</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Characterizing a psychiatric symptom dimension related to deficits in goal-directed control</article-title><source>eLife</source><volume>5</volume><elocation-id>e11305</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.11305</pub-id><pub-id pub-id-type="pmid">26928075</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The cortical dopamine system: role in memory and cognition</article-title><source>Advances in Pharmacology</source><volume>6</volume><elocation-id>60846-7</elocation-id><pub-id pub-id-type="doi">10.1016/S1054-3589(08)60846-7</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedges</surname><given-names>LV</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Effect sizes in cluster-randomized designs</article-title><source>Journal of Educational and Behavioral Statistics</source><volume>32</volume><fpage>341</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.3102/1076998606298043</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahnt</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>SC</given-names></name><name><surname>Haker</surname><given-names>H</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Tobler</surname><given-names>PN</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dopamine D2-receptor blockade enhances decoding of prefrontal signals in humans</article-title><source>The Journal of Neuroscience</source><volume>35</volume><fpage>4104</fpage><lpage>4111</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4182-14.2015</pub-id><pub-id pub-id-type="pmid">25740537</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Klaus</surname><given-names>J</given-names></name><name><surname>Schriefers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Measuring verbal working memory capacity: A reading span task for laboratory and web-based use</data-title><source>Open Science Framework</source><ext-link ext-link-type="uri" xlink:href="https://doi.org.10.31219/osf.io/nj48x">https://doi.org.10.31219/osf.io/nj48x</ext-link></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koob</surname><given-names>GF</given-names></name><name><surname>Bloom</surname><given-names>FE</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Cellular and molecular mechanisms of drug dependence</article-title><source>Science</source><volume>242</volume><fpage>715</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1126/science.2903550</pub-id><pub-id pub-id-type="pmid">2903550</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kool</surname><given-names>W</given-names></name><name><surname>Cushman</surname><given-names>FA</given-names></name><name><surname>Gershman</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>When does model-based control pay off?</article-title><source>PLOS Computational Biology</source><volume>12</volume><elocation-id>e1005090</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005090</pub-id><pub-id pub-id-type="pmid">27564094</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kool</surname><given-names>W</given-names></name><name><surname>Gershman</surname><given-names>SJ</given-names></name><name><surname>Cushman</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cost-Benefit arbitration between multiple reinforcement-learning systems</article-title><source>Psychological Science</source><volume>28</volume><fpage>1321</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1177/0956797617708288</pub-id><pub-id pub-id-type="pmid">28731839</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kool</surname><given-names>W</given-names></name><name><surname>Botvinick</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mental labour</article-title><source>Nature Human Behaviour</source><volume>2</volume><fpage>899</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1038/s41562-018-0401-9</pub-id><pub-id pub-id-type="pmid">30988433</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korb</surname><given-names>S</given-names></name><name><surname>Götzendorfer</surname><given-names>SJ</given-names></name><name><surname>Massaccesi</surname><given-names>C</given-names></name><name><surname>Sezen</surname><given-names>P</given-names></name><name><surname>Graf</surname><given-names>I</given-names></name><name><surname>Willeit</surname><given-names>M</given-names></name><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Silani</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dopaminergic and opioidergic regulation during anticipation and consumption of social and nonsocial rewards</article-title><source>eLife</source><volume>9</volume><elocation-id>e55797</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.55797</pub-id><pub-id pub-id-type="pmid">33046213</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname><given-names>NB</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Pooseh</surname><given-names>S</given-names></name><name><surname>Eppinger</surname><given-names>B</given-names></name><name><surname>Goschke</surname><given-names>T</given-names></name><name><surname>Smolka</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>L-Dopa reduces model-free control of behavior by attenuating the transfer of value to action</article-title><source>NeuroImage</source><volume>186</volume><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.10.075</pub-id><pub-id pub-id-type="pmid">30381245</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kruschke</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2014">2014</year><source>Doing Bayesian Data Analysis: A Tutorial with R, JAGS, and Stan</source><publisher-name>Academic Press</publisher-name><pub-id pub-id-type="doi">10.1016/B978-0-12-405888-0.09999-2</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laakso</surname><given-names>A</given-names></name><name><surname>Pohjalainen</surname><given-names>T</given-names></name><name><surname>Bergman</surname><given-names>J</given-names></name><name><surname>Kajander</surname><given-names>J</given-names></name><name><surname>Haaparanta</surname><given-names>M</given-names></name><name><surname>Solin</surname><given-names>O</given-names></name><name><surname>Syvälahti</surname><given-names>E</given-names></name><name><surname>Hietala</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects</article-title><source>Pharmacogenetics and Genomics</source><volume>15</volume><fpage>387</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1097/01213011-200506000-00003</pub-id><pub-id pub-id-type="pmid">15900211</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langdon</surname><given-names>AJ</given-names></name><name><surname>Sharpe</surname><given-names>MJ</given-names></name><name><surname>Schoenbaum</surname><given-names>G</given-names></name><name><surname>Niv</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Model-Based predictions for dopamine</article-title><source>Current Opinion in Neurobiology</source><volume>49</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2017.10.006</pub-id><pub-id pub-id-type="pmid">29096115</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurent</surname><given-names>V</given-names></name><name><surname>Leung</surname><given-names>B</given-names></name><name><surname>Maidment</surname><given-names>N</given-names></name><name><surname>Balleine</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Μ- and δ-opioid-related processes in the accumbens core and shell differentially mediate the influence of reward-guided and stimulus-guided decisions on choice</article-title><source>The Journal of Neuroscience</source><volume>32</volume><fpage>1875</fpage><lpage>1883</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4688-11.2012</pub-id><pub-id pub-id-type="pmid">22302826</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Wagner</surname><given-names>HN</given-names></name><name><surname>Tanada</surname><given-names>S</given-names></name><name><surname>Frost</surname><given-names>JJ</given-names></name><name><surname>Bice</surname><given-names>AN</given-names></name><name><surname>Dannals</surname><given-names>RF</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Duration of occupancy of opiate receptors by naltrexone</article-title><source>Journal of Nuclear Medicine</source><volume>29</volume><fpage>1207</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">2839637</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Merrer</surname><given-names>J</given-names></name><name><surname>Becker</surname><given-names>JAJ</given-names></name><name><surname>Befort</surname><given-names>K</given-names></name><name><surname>Kieffer</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Reward processing by the opioid system in the brain</article-title><source>Physiological Reviews</source><volume>89</volume><fpage>1379</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1152/physrev.00005.2009</pub-id><pub-id pub-id-type="pmid">19789384</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengersdorff</surname><given-names>LL</given-names></name><name><surname>Wagner</surname><given-names>IC</given-names></name><name><surname>Lockwood</surname><given-names>PL</given-names></name><name><surname>Lamm</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>When implicit prosociality trumps selfishness: the neural valuation system underpins more optimal choices when learning to avoid harm to others than to oneself</article-title><source>The Journal of Neuroscience</source><volume>40</volume><fpage>7286</fpage><lpage>7299</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0842-20.2020</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Männistö</surname><given-names>PT</given-names></name><name><surname>Kaakkola</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Catechol-O-Methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors</article-title><source>Pharmacological Reviews</source><volume>51</volume><fpage>593</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">10581325</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martín del Campo</surname><given-names>AF</given-names></name><name><surname>McMurray</surname><given-names>RG</given-names></name><name><surname>Besser</surname><given-names>GM</given-names></name><name><surname>Grossman</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Effect of 12-hour infusion of naloxone on mood and cognition in normal male volunteers</article-title><source>Biological Psychiatry</source><volume>32</volume><fpage>344</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/0006-3223(92)90038-2</pub-id><pub-id pub-id-type="pmid">1420648</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McElreath</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Statistical Rethinking: A Bayesian Course with Examples in R and Stan</source><publisher-name>CRC press</publisher-name><pub-id pub-id-type="doi">10.1201/9781315372495</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNab</surname><given-names>F</given-names></name><name><surname>Klingberg</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prefrontal cortex and basal ganglia control access to working memory</article-title><source>Nature Neuroscience</source><volume>11</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nn2024</pub-id><pub-id pub-id-type="pmid">18066057</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>MA</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name><name><surname>McKenna</surname><given-names>PJ</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson’s disease</article-title><source>Psychopharmacology</source><volume>146</volume><fpage>162</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1007/s002130051102</pub-id><pub-id pub-id-type="pmid">10525751</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>MA</given-names></name><name><surname>Manes</surname><given-names>FF</given-names></name><name><surname>Magnolfi</surname><given-names>G</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers</article-title><source>Psychopharmacology</source><volume>176</volume><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1007/s00213-004-1899-2</pub-id><pub-id pub-id-type="pmid">15114435</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melnikoff</surname><given-names>DE</given-names></name><name><surname>Bargh</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The mythical number two</article-title><source>Trends in Cognitive Sciences</source><volume>22</volume><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.tics.2018.02.001</pub-id><pub-id pub-id-type="pmid">29571664</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Mikus</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Mbmf-da-op</data-title><version designator="swh:1:rev:4822b12aa33d8e5eb60d8ad5af2a0d3392e00e20">swh:1:rev:4822b12aa33d8e5eb60d8ad5af2a0d3392e00e20</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:47f15ecdba3571787c7da237ce64f09a3a6afef6;origin=https://github.com/nacemikus/mbmf-da-op;visit=swh:1:snp:9490c0a2d0cad62b71a32f2a692ec91b8fb3626b;anchor=swh:1:rev:4822b12aa33d8e5eb60d8ad5af2a0d3392e00e20">https://archive.softwareheritage.org/swh:1:dir:47f15ecdba3571787c7da237ce64f09a3a6afef6;origin=https://github.com/nacemikus/mbmf-da-op;visit=swh:1:snp:9490c0a2d0cad62b71a32f2a692ec91b8fb3626b;anchor=swh:1:rev:4822b12aa33d8e5eb60d8ad5af2a0d3392e00e20</ext-link></element-citation></ref><ref id="bib65"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Mikus</surname><given-names>N</given-names></name><name><surname>Eisenegger</surname><given-names>C</given-names></name><name><surname>Mathys</surname><given-names>C</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Lamm</surname><given-names>C</given-names></name><name><surname>Naef</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Blocking D2/D3 Dopamine Receptors Increases Volatility of Beliefs When We Learn to Trust Others</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.06.21.496956</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montague</surname><given-names>PR</given-names></name><name><surname>Dayan</surname><given-names>P</given-names></name><name><surname>Sejnowski</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A framework for mesencephalic dopamine systems based on predictive Hebbian learning</article-title><source>The Journal of Neuroscience</source><volume>16</volume><fpage>1936</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.16-05-01936.1996</pub-id><pub-id pub-id-type="pmid">8774460</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naef</surname><given-names>M</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name><name><surname>Linssen</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>L</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Eisenegger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effects of dopamine D2/D3 receptor antagonism on human planning and spatial working memory</article-title><source>Translational Psychiatry</source><volume>7</volume><elocation-id>e1107</elocation-id><pub-id pub-id-type="doi">10.1038/tp.2017.56</pub-id><pub-id pub-id-type="pmid">28440817</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalborczyk</surname><given-names>L</given-names></name><name><surname>Batailler</surname><given-names>C</given-names></name><name><surname>Lœvenbruck</surname><given-names>H</given-names></name><name><surname>Vilain</surname><given-names>A</given-names></name><name><surname>Bürkner</surname><given-names>P-C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An introduction to Bayesian multilevel models using brms: a case study of gender effects on vowel variability in standard Indonesian</article-title><source>Journal of Speech, Language, and Hearing Research</source><volume>62</volume><fpage>1225</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1044/2018_JSLHR-S-18-0006</pub-id><pub-id pub-id-type="pmid">31082309</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niv</surname><given-names>Y</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name><name><surname>Joel</surname><given-names>D</given-names></name><name><surname>Dayan</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Tonic dopamine: opportunity costs and the control of response vigor</article-title><source>Psychopharmacology</source><volume>191</volume><fpage>507</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0502-4</pub-id><pub-id pub-id-type="pmid">17031711</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>AR</given-names></name><name><surname>Gershman</surname><given-names>SJ</given-names></name><name><surname>Markman</surname><given-names>AB</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>The curse of planning: dissecting multiple reinforcement-learning systems by taxing the central executive</article-title><source>Psychological Science</source><volume>24</volume><fpage>751</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1177/0956797612463080</pub-id><pub-id pub-id-type="pmid">23558545</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>AR</given-names></name><name><surname>Raio</surname><given-names>CM</given-names></name><name><surname>Chiang</surname><given-names>A</given-names></name><name><surname>Phelps</surname><given-names>EA</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Working-memory capacity protects model-based learning from stress</article-title><source>PNAS</source><volume>110</volume><fpage>20941</fpage><lpage>20946</lpage><pub-id pub-id-type="doi">10.1073/pnas.1312011110</pub-id><pub-id pub-id-type="pmid">24324166</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patzelt</surname><given-names>EH</given-names></name><name><surname>Kool</surname><given-names>W</given-names></name><name><surname>Millner</surname><given-names>AJ</given-names></name><name><surname>Gershman</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Incentives boost model-based control across a range of severity on several psychiatric constructs</article-title><source>Biological Psychiatry</source><volume>85</volume><fpage>425</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2018.06.018</pub-id><pub-id pub-id-type="pmid">30077331</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peciña</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Opioid reward “ liking ” and “ wanting ” in the nucleus accumbens</article-title><source>Physiology &amp; Behavior</source><volume>94</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2008.04.006</pub-id><pub-id pub-id-type="pmid">18513761</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peciña</surname><given-names>S</given-names></name><name><surname>Berridge</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dopamine or opioid stimulation of nucleus accumbens similarly amplify cue-triggered “ wanting ” for reward: entire core and medial shell mapped as substrates for pit enhancement</article-title><source>The European Journal of Neuroscience</source><volume>37</volume><fpage>1529</fpage><lpage>1540</lpage><pub-id pub-id-type="doi">10.1111/ejn.12174</pub-id><pub-id pub-id-type="pmid">23495790</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelloux</surname><given-names>Y</given-names></name><name><surname>Dilleen</surname><given-names>R</given-names></name><name><surname>Economidou</surname><given-names>D</given-names></name><name><surname>Theobald</surname><given-names>D</given-names></name><name><surname>Everitt</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats</article-title><source>Neuropsychopharmacology</source><volume>37</volume><fpage>2505</fpage><lpage>2514</lpage><pub-id pub-id-type="doi">10.1038/npp.2012.111</pub-id><pub-id pub-id-type="pmid">22763621</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Herdener</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Human pharmacology for addiction medicine: from evidence to clinical recommendations</article-title><source>Progress in Brain Research</source><volume>224</volume><fpage>227</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/bs.pbr.2015.07.017</pub-id><pub-id pub-id-type="pmid">26822361</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenzweig</surname><given-names>P</given-names></name><name><surname>Canal</surname><given-names>M</given-names></name><name><surname>Patat</surname><given-names>A</given-names></name><name><surname>Bergougnan</surname><given-names>L</given-names></name><name><surname>Zieleniuk</surname><given-names>I</given-names></name><name><surname>Bianchetti</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers</article-title><source>Human Psychopharmacology</source><volume>17</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1002/hup.320</pub-id><pub-id pub-id-type="pmid">12404702</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salamone</surname><given-names>JD</given-names></name><name><surname>Correa</surname><given-names>M</given-names></name><name><surname>Yohn</surname><given-names>S</given-names></name><name><surname>Lopez Cruz</surname><given-names>L</given-names></name><name><surname>San Miguel</surname><given-names>N</given-names></name><name><surname>Alatorre</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The pharmacology of effort-related choice behavior: dopamine, depression, and individual differences</article-title><source>Behavioural Processes</source><volume>127</volume><fpage>3</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.beproc.2016.02.008</pub-id><pub-id pub-id-type="pmid">26899746</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawaguchi</surname><given-names>T</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>D1 dopamine receptors in prefrontal cortex: involvement in working memory</article-title><source>Science</source><volume>251</volume><fpage>947</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1126/science.1825731</pub-id><pub-id pub-id-type="pmid">1825731</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoemaker</surname><given-names>H</given-names></name><name><surname>Claustre</surname><given-names>Y</given-names></name><name><surname>Fage</surname><given-names>D</given-names></name><name><surname>Rouquier</surname><given-names>L</given-names></name><name><surname>Chergui</surname><given-names>K</given-names></name><name><surname>Curet</surname><given-names>O</given-names></name><name><surname>Oblin</surname><given-names>A</given-names></name><name><surname>Gonon</surname><given-names>F</given-names></name><name><surname>Carter</surname><given-names>C</given-names></name><name><surname>Benavides</surname><given-names>J</given-names></name><name><surname>Scatton</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>280</volume><fpage>83</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">8996185</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>W</given-names></name><name><surname>Dayan</surname><given-names>P</given-names></name><name><surname>Montague</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A neural substrate of prediction and reward</article-title><source>Science</source><volume>275</volume><fpage>1593</fpage><lpage>1599</lpage><pub-id pub-id-type="doi">10.1126/science.275.5306.1593</pub-id><pub-id pub-id-type="pmid">9054347</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seamans</surname><given-names>JK</given-names></name><name><surname>Yang</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The principal features and mechanisms of dopamine modulation in the prefrontal cortex</article-title><source>Progress in Neurobiology</source><volume>74</volume><fpage>1</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2004.05.006</pub-id><pub-id pub-id-type="pmid">15381316</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seth</surname><given-names>P</given-names></name><name><surname>Scholl</surname><given-names>L</given-names></name><name><surname>Rudd</surname><given-names>RA</given-names></name><name><surname>Bacon</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Overdose deaths involving opioids, cocaine, and psychostimulants — united states, 2015–2016</article-title><source>American Journal of Transplantation</source><volume>18</volume><fpage>1556</fpage><lpage>1568</lpage><pub-id pub-id-type="doi">10.1111/ajt.14905</pub-id><pub-id pub-id-type="pmid">29878638</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>ME</given-names></name><name><surname>Foerde</surname><given-names>K</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name><name><surname>Shohamy</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dopamine selectively remediates “ model-based ” reward learning: a computational approach</article-title><source>Brain</source><volume>139</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1093/brain/awv347</pub-id><pub-id pub-id-type="pmid">26685155</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares-Cunha</surname><given-names>C</given-names></name><name><surname>Coimbra</surname><given-names>B</given-names></name><name><surname>David-Pereira</surname><given-names>A</given-names></name><name><surname>Borges</surname><given-names>S</given-names></name><name><surname>Pinto</surname><given-names>L</given-names></name><name><surname>Costa</surname><given-names>P</given-names></name><name><surname>Sousa</surname><given-names>N</given-names></name><name><surname>Rodrigues</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Activation of D2 dopamine receptor-expressing neurons in the nucleus accumbens increases motivation</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11829</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11829</pub-id><pub-id pub-id-type="pmid">27337658</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soutschek</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>SC</given-names></name><name><surname>Kahnt</surname><given-names>T</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Tobler</surname><given-names>PN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Opioid antagonism modulates wanting-related frontostriatal connectivity</article-title><source>eLife</source><volume>10</volume><elocation-id>e71077</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.71077</pub-id><pub-id pub-id-type="pmid">34761749</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sridharan</surname><given-names>D</given-names></name><name><surname>Prashanth</surname><given-names>PS</given-names></name><name><surname>Chakravarthy</surname><given-names>VS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The role of the basal ganglia in exploration in a neural model based on reinforcement learning</article-title><source>International Journal of Neural Systems</source><volume>16</volume><fpage>111</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1142/S0129065706000548</pub-id><pub-id pub-id-type="pmid">16688851</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stalnaker</surname><given-names>TA</given-names></name><name><surname>Howard</surname><given-names>JD</given-names></name><name><surname>Takahashi</surname><given-names>YK</given-names></name><name><surname>Gershman</surname><given-names>SJ</given-names></name><name><surname>Kahnt</surname><given-names>T</given-names></name><name><surname>Schoenbaum</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dopamine neuron ensembles signal the content of sensory prediction errors</article-title><source>eLife</source><volume>8</volume><elocation-id>e49315</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.49315</pub-id><pub-id pub-id-type="pmid">31674910</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname><given-names>RS</given-names></name><name><surname>Barto</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Reinforcement learning: an introduction</article-title><source>IEEE Transactions on Neural Networks</source><volume>9</volume><elocation-id>1054</elocation-id><pub-id pub-id-type="doi">10.1109/TNN.1998.712192</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takano</surname><given-names>A</given-names></name><name><surname>Suhara</surname><given-names>T</given-names></name><name><surname>Yasuno</surname><given-names>F</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Morimoto</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>Y-J</given-names></name><name><surname>Kusuhara</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name><name><surname>Okubo</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The antipsychotic sultopride is overdosed -- a PET study of drug-induced receptor occupancy in comparison with sulpiride</article-title><source>The International Journal of Neuropsychopharmacology</source><volume>9</volume><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1017/S1461145705006103</pub-id><pub-id pub-id-type="pmid">16288681</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trantham-Davidson</surname><given-names>H</given-names></name><name><surname>Neely</surname><given-names>LC</given-names></name><name><surname>Lavin</surname><given-names>A</given-names></name><name><surname>Seamans</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex</article-title><source>The Journal of Neuroscience</source><volume>24</volume><fpage>10652</fpage><lpage>10659</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3179-04.2004</pub-id><pub-id pub-id-type="pmid">15564581</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Trøstheim</surname><given-names>M</given-names></name><name><surname>Eikemo</surname><given-names>M</given-names></name><name><surname>Haaker</surname><given-names>J</given-names></name><name><surname>Frost</surname><given-names>JJ</given-names></name><name><surname>Leknes</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Opioid Antagonism in Humans: A Primer on Optimal Dose and Timing for Central Mu-Opioid Receptor Blockade</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.02.25.481943</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Schouwenburg</surname><given-names>M</given-names></name><name><surname>Aarts</surname><given-names>E</given-names></name><name><surname>Cools</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Dopaminergic modulation of cognitive control: distinct roles for the prefrontal cortex and the basal ganglia</article-title><source>Current Pharmaceutical Design</source><volume>16</volume><fpage>2026</fpage><lpage>2032</lpage><pub-id pub-id-type="doi">10.2174/138161210791293097</pub-id><pub-id pub-id-type="pmid">20370667</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Steenbergen</surname><given-names>H</given-names></name><name><surname>Eikemo</surname><given-names>M</given-names></name><name><surname>Leknes</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of the opioid system in decision making and cognitive control: a review</article-title><source>Cognitive, Affective &amp; Behavioral Neuroscience</source><volume>19</volume><fpage>435</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.3758/s13415-019-00710-6</pub-id><pub-id pub-id-type="pmid">30963411</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vehtari</surname><given-names>A</given-names></name><name><surname>Gelman</surname><given-names>A</given-names></name><name><surname>Gabry</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC</article-title><source>Statistics and Computing</source><volume>27</volume><fpage>1413</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1007/s11222-016-9696-4</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volavka</surname><given-names>J</given-names></name><name><surname>Dornbush</surname><given-names>R</given-names></name><name><surname>Mallya</surname><given-names>A</given-names></name><name><surname>Cho</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Naloxone fails to affect short-term memory in man</article-title><source>Psychiatry Research</source><volume>1</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/0165-1781(79)90032-5</pub-id><pub-id pub-id-type="pmid">298342</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>V</given-names></name><name><surname>Derbyshire</surname><given-names>K</given-names></name><name><surname>Rück</surname><given-names>C</given-names></name><name><surname>Irvine</surname><given-names>MA</given-names></name><name><surname>Worbe</surname><given-names>Y</given-names></name><name><surname>Enander</surname><given-names>J</given-names></name><name><surname>Schreiber</surname><given-names>LRN</given-names></name><name><surname>Gillan</surname><given-names>C</given-names></name><name><surname>Fineberg</surname><given-names>NA</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Harrison</surname><given-names>NA</given-names></name><name><surname>Wood</surname><given-names>J</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name><name><surname>Dayan</surname><given-names>P</given-names></name><name><surname>Grant</surname><given-names>JE</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Disorders of compulsivity: a common bias towards learning habits</article-title><source>Molecular Psychiatry</source><volume>20</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1038/mp.2014.44</pub-id><pub-id pub-id-type="pmid">24840709</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>V</given-names></name><name><surname>Reiter</surname><given-names>AMF</given-names></name><name><surname>Sebold</surname><given-names>M</given-names></name><name><surname>Groman</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Model-Based control in dimensional psychiatry</article-title><source>Biological Psychiatry</source><volume>82</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2017.04.006</pub-id><pub-id pub-id-type="pmid">28599832</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voon</surname><given-names>V</given-names></name><name><surname>Joutsa</surname><given-names>J</given-names></name><name><surname>Majuri</surname><given-names>J</given-names></name><name><surname>Baek</surname><given-names>K</given-names></name><name><surname>Nord</surname><given-names>CL</given-names></name><name><surname>Arponen</surname><given-names>E</given-names></name><name><surname>Forsback</surname><given-names>S</given-names></name><name><surname>Kaasinen</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The neurochemical substrates of habitual and goal-directed control</article-title><source>Translational Psychiatry</source><volume>10</volume><elocation-id>84</elocation-id><pub-id pub-id-type="doi">10.1038/s41398-020-0762-5</pub-id><pub-id pub-id-type="pmid">32127520</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wassum</surname><given-names>KM</given-names></name><name><surname>Cely</surname><given-names>IC</given-names></name><name><surname>Maidment</surname><given-names>NT</given-names></name><name><surname>Balleine</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Disruption of endogenous opioid activity during instrumental learning enhances habit acquisition</article-title><source>Neuroscience</source><volume>163</volume><fpage>770</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.06.071</pub-id><pub-id pub-id-type="pmid">19619616</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>SC</given-names></name><name><surname>Beck-Schimmer</surname><given-names>B</given-names></name><name><surname>Kajdi</surname><given-names>M-E</given-names></name><name><surname>Müller</surname><given-names>D</given-names></name><name><surname>Tobler</surname><given-names>PN</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dopamine D2/3- and μ-opioid receptor antagonists reduce cue-induced responding and reward impulsivity in humans</article-title><source>Translational Psychiatry</source><volume>6</volume><elocation-id>e850</elocation-id><pub-id pub-id-type="doi">10.1038/tp.2016.113</pub-id><pub-id pub-id-type="pmid">27378550</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westbrook</surname><given-names>A</given-names></name><name><surname>van den Bosch</surname><given-names>R</given-names></name><name><surname>Määttä</surname><given-names>JI</given-names></name><name><surname>Hofmans</surname><given-names>L</given-names></name><name><surname>Papadopetraki</surname><given-names>D</given-names></name><name><surname>Cools</surname><given-names>R</given-names></name><name><surname>Frank</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work</article-title><source>Science</source><volume>367</volume><fpage>1362</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1126/science.aaz5891</pub-id><pub-id pub-id-type="pmid">32193325</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westbrook</surname><given-names>A</given-names></name><name><surname>Frank</surname><given-names>MJ</given-names></name><name><surname>Cools</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A mosaic of cost-benefit control over cortico-striatal circuitry</article-title><source>Trends in Cognitive Sciences</source><volume>25</volume><fpage>710</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/j.tics.2021.04.007</pub-id><pub-id pub-id-type="pmid">34120845</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>GV</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Modulation of memory fields by dopamine D1 receptors in prefrontal cortex</article-title><source>Nature</source><volume>376</volume><fpage>572</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/376572a0</pub-id><pub-id pub-id-type="pmid">7637804</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worbe</surname><given-names>Y</given-names></name><name><surname>Savulich</surname><given-names>G</given-names></name><name><surname>de Wit</surname><given-names>S</given-names></name><name><surname>Fernandez-Egea</surname><given-names>E</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Tryptophan depletion promotes habitual over goal-directed control of appetitive responding in humans</article-title><source>The International Journal of Neuropsychopharmacology</source><volume>18</volume><elocation-id>pyv013</elocation-id><pub-id pub-id-type="doi">10.1093/ijnp/pyv013</pub-id><pub-id pub-id-type="pmid">25663044</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Medical association Declaration of Helsinki</collab></person-group><year iso-8601-date="2013">2013</year><article-title>World medical association declaration of helsinki</article-title><source>JAMA</source><volume>310</volume><elocation-id>2191</elocation-id><pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">24141714</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wunderlich</surname><given-names>K</given-names></name><name><surname>Smittenaar</surname><given-names>P</given-names></name><name><surname>Dolan</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dopamine enhances model-based over model-free choice behavior</article-title><source>Neuron</source><volume>75</volume><fpage>418</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.042</pub-id><pub-id pub-id-type="pmid">22884326</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Vehtari</surname><given-names>A</given-names></name><name><surname>Simpson</surname><given-names>D</given-names></name><name><surname>Gelman</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Using stacking to average bayesian predictive distributions (with discussion)</article-title><source>Bayesian Analysis</source><volume>13</volume><elocation-id>BA1091</elocation-id><pub-id pub-id-type="doi">10.1214/17-BA1091</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zacny</surname><given-names>JP</given-names></name><name><surname>Coalson</surname><given-names>DW</given-names></name><name><surname>Lichtor</surname><given-names>JL</given-names></name><name><surname>Yajnik</surname><given-names>S</given-names></name><name><surname>Thapar</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Effects of naloxone on the subjective and psychomotor effects of nitrous oxide in humans</article-title><source>Pharmacology, Biochemistry, and Behavior</source><volume>49</volume><fpage>573</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(94)90071-x</pub-id><pub-id pub-id-type="pmid">7862710</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lengersdorff</surname><given-names>L</given-names></name><name><surname>Mikus</surname><given-names>N</given-names></name><name><surname>Gläscher</surname><given-names>J</given-names></name><name><surname>Lamm</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Using reinforcement learning models in social neuroscience: frameworks, pitfalls and suggestions of best practices</article-title><source>Social Cognitive and Affective Neuroscience</source><volume>15</volume><fpage>695</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1093/scan/nsaa089</pub-id><pub-id pub-id-type="pmid">32608484</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79661.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kahnt</surname><given-names>Thorsten</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fq5cm18</institution-id><institution>National Institute on Drug Abuse Intramural Research Program</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.03.03.482871" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.03.482871"/></front-stub><body><p>This study provides novel evidence that a dopamine D2/D3 receptor antagonist enhances model-based control of behavior, whereas blocking opioid receptors has no effect. These conclusions are based on compelling behavioral and computational modeling data. The paper makes an important contribution to our understanding of how dopamine shifts the balance between two subsystems regulating behavior and may improve the understanding of motivational dysfunctions in mental disorders like addiction.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79661.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Kahnt</surname><given-names>Thorsten</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fq5cm18</institution-id><institution>National Institute on Drug Abuse Intramural Research Program</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.03.03.482871">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.03.03.482871v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Effects of dopamine D2 and opioid receptor antagonism on the trade-off between model-based and model-free behaviour in healthy volunteers&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and Michael Taffe as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The reviewers agree that your paper is solid, timely, and interesting but that a few issues have to be addressed.</p><p>Please address the comments in the individual reviews, with a particular emphasis on the following points:</p><p>1) Provide a better motivation for studying the effects of these two drugs and specific predictions for their effects.</p><p>2) Revise the statistical analysis to include additional random effects.</p><p>3) Discuss the issue that baseline and drug sessions are not counter-balanced as limitations.</p><p>4) Include drug serum levels in the analysis.</p><p>5) Elaborate on the detrimental effects of amisulpride on stay-choices when the first stage stays the same.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Please include serum levels for amisulpride and naltrexone should be included as covariates in the analysis.</p><p>It's not entirely clear to me how the detrimental effect of amisulpride on high-point repeat choices when the first stage stays the same (which I believe is captured by the inverse temperature) can be reconciled with the idea that blocking D2 receptors reduces flexibility and enhances the stability of prefrontal representations.</p><p>If I understand the models correctly, the only difference between the three models is the number of free learning rates. The learning rate in M1 is set to 1, and M2 and M3 allow two or one free learning rate. If this is correct, it would be easier to just describe it like that rather than presenting them as fundamentally different models.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. One motivation for the study is that dopamine agonists yielded inconsistent results, but also the effects of D2 antagonists like amisulpride are not straightforward to interpret. This is because the administered dose of 400 mg can lead to either presynaptic effects (which increases dopaminergic activity) or postsynaptic effects (reducing dopaminergic activity, as assumed by the authors). Participants with a lower effective dose may show stronger presynaptic than postsynaptic effects, and vice versa for individuals with a higher effective dose. To control for the effective dose, the authors might use the measured plasma concentrations. If the current interpretation is correct, the impact of amisulpride on the weighing parameter should increase with higher plasma concentrations, suggesting that the observed mean effect would be driven by postsynaptic rather than presynaptic mechanisms.</p><p>2. According to supplementary Table 1, only the main effects of &quot;session&quot;, &quot;prev_state_diff&quot;, and &quot;prev_points&quot; were modelled as random slopes, whereas as fixed effects also all interaction terms were modelled. As it is generally recommended to maximize the random effects matrix in order to reduce the risk of false positives, I ask the authors to model also the interaction terms between these variables as random slopes. Does this change the observed amisulpride effects?</p><p>3. Why did the authors control for BMI (supplementary Table 5)? If the intention was to control for the effective individual dose, body weight would be more relevant than BMI.</p><p>4. The inverse temperature parameter in the computational model is described as an indicator of both exploratory behavior and decision noise. Is exploratory behavior the same as decision noise in the current task, or does one parameter indeed measure two dissociable constructs?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Here are two small comments about the analyses. First, why didn't the authors include stickiness parameters in the model? This is very popular in our field because it allows us to capture variance in choice induced by preferences that are not related to maximizing reward. Second, the behavioral analysis that tests the effect of a previous reward on choice is not quite ideal, because it doesn't take into account that the same scalar reward (e.g., +1 point) can elicit a negative prediction error (if you expected +5) or a positive prediction error (if you expected -3). This issue can be remedied by computing prediction errors for the second-stage reward and then using their sign as a predictor of staying behavior.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Effects of dopamine D2 and opioid receptor antagonism on the trade-off between model-based and model-free behaviour in healthy volunteers&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by Michael Taffe (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>As suggested by reviewer #2, please repeat the analyses using continuous rather than categorical plasma levels (or justify the use of a categorical variable), and also include plasma levels for the model-free behavioral analyses.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors have done a very nice job addressing my initial comments. I don't have any additional points.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The authors made a good job of revising the manuscript and successfully addressed almost all of my previous concerns. However, I still have some questions regarding the inclusion of plasma concentrations in the statistical analyses: First, I wondered why plasma concentrations were dichotomized into low versus high (and was this done based on the mean or the median)? It seems more straightforward to enter plasma concentrations as continuous predictors to the models, as this takes the full variation in plasma concentrations between individuals into account. Second, it seems that plasma concentrations were added only to the model-based computational analyses, but in order to be consistent the authors should do the same with their model-free behavioral analyses.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79661.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Please include serum levels for amisulpride and naltrexone should be included as covariates in the analysis.</p></disp-quote><p>We thank the reviewer for the excellent suggestion to also include serum levels as covariates. Doing so had a profound impact on the interpretation of the results of our study. By including the serum variable, it became clear that the increased exploration is predominantly observed in participants with high amisulpride serum levels in the blood, whereas the increase in the model-based weight did not scale with serum levels (see Figure 5). We note also that the blood samples of the naltrexone group were not analysed, based on the finding that 50 mg provides abundant (~90%) and consistent occupancy of opioid receptors (Trøstheim, Eikemo, Haaker, Frost, and Leknes, 2022).</p><p>The following text is now included in the results (p.6 §3,4):</p><p>“We next looked at whether the effects of amisulpride were different based on the effective dose. We reran the parameter estimation including a variable for amisulpride blood serum levels (Figure 5). We found that amisulpride increased <inline-formula><mml:math id="sa2m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> in both the low serum group (b = 0.919, 95% CI [0.216, 1.722], P(b&lt;0) = 0.006, d = 1.013, 95% CI [0.238, 1.897]) and the high serum group (b = 0.872, 95% CI [0.008, 1.853], P(b&lt;0) = 0.024, d = 0.961, 95% CI [0.009, 2.041]), with no difference between the effects (P(b&gt;0) = 0.458). However, when looking at the effects of amisulpride on <inline-formula><mml:math id="sa2m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> we found that it was not reduced in the low serum group (b = -0.105, 95% CI [-0.523, 0.348], P(b&gt;0) = 0.323, d = -0.096, 95% CI [-0.477, 0.317]), but was reduced in the high serum group (b = -0.492, 95% CI [-0.96, -0.033], P(b&gt;0) = 0.018, d = -0.45, 95% CI [-0.877, -0.03]), with a (non-significant) moderate effect size difference between the effects (b = -0.393, 95% CI [-0.918, 0.118], P(b&gt;0) = 0.066, d = -0.359, 95% CI [-0.838, 0.108]).</p><p>Lower values of <inline-formula><mml:math id="sa2m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> imply more choice behaviour that the model cannot explain based on estimated values of the two spaceships. To see whether some of the increased variance can be explained by the tendency of participants to repeat actions or choices regardless of outcomes, we extended the M1 serum model to include a response stickiness (<inline-formula><mml:math id="sa2m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) and stimulus stickiness (<inline-formula><mml:math id="sa2m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>π</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>) parameter. We found some evidence that amisulpride in participants with high serum levels increased switching between responses, as indicated by the reduced <inline-formula><mml:math id="sa2m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> parameter (b = -0.466, 95% CI [-0.962, 0.043], P(b&gt;0) = 0.039). This effect was not present in the low serum group (b = -0.158, 95% CI [-0.618, 0.311], P(b&gt;0) = 0.251), with a non-significant difference between the effects (b = -0.294, 95% CI [-0.723, 0.13], P(b&gt;0) = 0.082). The inclusion of the two stickiness parameters, did not markedly change the posterior distributions of effects of amisulpride on <inline-formula><mml:math id="sa2m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, but did reduce the effect on <inline-formula><mml:math id="sa2m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> in the high serum group (b = 0.571, 95% CI [-0.361, 1.527], P(b&lt;0) = 0.111, see Figure 4 —figure supplement 2 for other relevant posterior distributions). We note however, that the model including stickiness parameters performed worse than the model without the stickiness parameters, with a lower out-of-sample trial-wise predictive performance (<inline-formula><mml:math id="sa2m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>Δelpd</mml:mtext></mml:mrow></mml:mstyle></mml:math></inline-formula>(sd) = -413 (31.5)).”</p><disp-quote content-type="editor-comment"><p>It's not entirely clear to me how the detrimental effect of amisulpride on high-point repeat choices when the first stage stays the same (which I believe is captured by the inverse temperature) can be reconciled with the idea that blocking D2 receptors reduces flexibility and enhances the stability of prefrontal representations.</p></disp-quote><p>We agree with the reviewer that this issue was not sufficiently discussed in the manuscript. As the reviewer points out – we now show that the subject-level random slope of “high-point repeat choices when the first stage stays the same” is indeed reflected in the inverse temperature parameter (p.6, §4). With the addition of serum data, we can speculate that the exploration could be mainly due to occupation of the post-synaptic D2 receptors, which are known to be involved in the exploration-exploitation trade-off and choice stochasticity. We also show that the random slope for different first stage stays is more related to the model-based/model-free weight. As mentioned above, this parameter does not scale with the serum levels suggesting the effect is not post-synaptic and is present already with small doses. This might imply that the increase in model-based weight is driven by presynaptic effects. However, there is also a line of research (the dual state theory of prefrontal dopamine function proposed by Durstewitz and Seamans, 2008) showing the role of prefrontal D2 in destabilisation of prefrontal representations. We therefore also present the argumentation that D2 receptor antagonists might increase stability of prefrontal representations which in turn helps explain the ability of subjects under amisulpride to maintain the mapping online. As the reviewer alluded to, this take on the effects is hard to reconcile with increased exploration and also with flexible adaptations of choice selection and fast action values updating that is required in this task. We elaborate on this in the discussion (p.8 §2):</p><p>“According to the dual-state theory of prefrontal dopamine function (Durstewitz and Seamans, 2008), a state dominated by D1 receptor activity is characterized by a high-energy barrier and supports stabilization of prefrontal representations. Conversely, a D2 receptor dominated state has a low-energy barrier and facilitates flexible switching between representational states. In line with this, D2 antagonists impair behaviour in tasks that require constant attentional set shifting (Mehta, Manes, Magnolfi, Sahakian, and Robbins, 2004), but might improve performance in tasks where prefrontal goal representations are required (Kahnt, Weber, Haker, Robbins, and Tobler, 2015). For example, D2 antagonism improves the ability of participants in certain cognitive tasks that require manipulation of task-relevant information in the working memory (Dodds et al., 2009; Frank and O’Reilly, 2006), but does not improve working memory capacity, or memory retrieval (Dodds et al., 2009; Mehta, Sahakian, McKenna, and Robbins, 1999; Naef et al., 2017). The effects of D2 antagonism on model-based/model-free behaviour in our study can be interpreted within this framework to result from increased ability to maintain prefrontal representation of the mapping between the spaceships and the planets online. However, this is difficult to reconcile with the fact that model-based behaviour in dynamic learning paradigms, such as the one used here, also requires flexible updating of action values.”</p><disp-quote content-type="editor-comment"><p>If I understand the models correctly, the only difference between the three models is the number of free learning rates. The learning rate in M1 is set to 1, and M2 and M3 allow two or one free learning rate. If this is correct, it would be easier to just describe it like that rather than presenting them as fundamentally different models.</p></disp-quote><p>We agree that the relationship between the three models should be explained better. The M1 model is indeed similar to the M2 and M3 models with fixed learning rates but also included the devaluation parameter on the not chosen option and omits the eligibility trace present in both M2 and M3 models. This has now been elaborated in the computational modelling part of the Results section.</p><p>The corresponding text (p. 5 §3) reads as follows:</p><p>“We compared the above-described model to two Dual-systems Reinforcement Learning (RL) models (Figure S1a). In these two models, the degree to which an outcome in each trial affects the subjective values of actions at each stage is determined by a learning rate parameter. The model-free agent thus learns the subjective action values in each stage from experience, by increasing the values of actions and states that lead to outcomes that were better than expected and decreasing the values when the outcome was worse than expected. We allow the learning rate at both stages to either be different (model M2) or the same (model M3). Note, that the model M1 is a version of these RL models, where the learning rates are set to 1 and a devaluation parameter is included on the non-chosen option. This is motivated by the observation that the rewards change according to a Gaussian random walk (and are not probabilistic), and therefore the last encountered outcome is the best guess the agent can make. When comparing the performance of the three models we found that the model M1 has better out of sample predictive accuracy compared to the other two models (Figure S1b). We verified the winning model with parameter recovery (Figure S1c) and posterior predictive checks (Figure S1d-f).”</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. One motivation for the study is that dopamine agonists yielded inconsistent results, but also the effects of D2 antagonists like amisulpride are not straightforward to interpret. This is because the administered dose of 400 mg can lead to either presynaptic effects (which increases dopaminergic activity) or postsynaptic effects (reducing dopaminergic activity, as assumed by the authors). Participants with a lower effective dose may show stronger presynaptic than postsynaptic effects, and vice versa for individuals with a higher effective dose. To control for the effective dose, the authors might use the measured plasma concentrations. If the current interpretation is correct, the impact of amisulpride on the weighing parameter should increase with higher plasma concentrations, suggesting that the observed mean effect would be driven by postsynaptic rather than presynaptic mechanisms.</p></disp-quote><p>We thank reviewer 2 for this constructive criticism and have now included serum levels in the analysis. This turned out to be of great value to pinpoint the effects of amisulpride. The newly provided Figure 5 (see below) shows that increased model-based weight did not scale with serum levels in the blood and was present in participants with either low or high serum levels. Further, we found that the higher exploration is predominantly observed in participants with high amisulpride serum levels in the blood and was not present in the low-serum group. Given that amisulpride might act on post-synaptic receptors with a higher effective dose this would be in-line with the well-established model of the role of postsynaptic D2 receptors corticostriatal loops in action selection and exploration. Our finding that we find an increase in the model-based weight already at low effective doses, might support the notion that the effect might be related to amisulpride increasing availability of dopamine in the synaptic cleft through blockade of the D2 autoreceptors.</p><p>These results are now described in the results (p.8-9) and in Figure 5:</p><p>“We next looked at whether the effects of amisulpride were different based on the effective dose. We reran the parameter estimation including a variable for amisulpride blood serum levels (Figure 5). We found that amisulpride increased <inline-formula><mml:math id="sa2m10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ω</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> in both the low serum group (b = 0.919, 95% CI [0.216, 1.722], P(b&lt;0) = 0.006, d = 1.013, 95% CI [0.238, 1.897]) and the high serum group (b = 0.872, 95% CI [0.008, 1.853], P(b&lt;0) = 0.024, d = 0.961, 95% CI [0.009, 2.041]), with no difference between the effects (P(b&gt;0) = 0.458). However, when looking at the effects of amisulpride on <inline-formula><mml:math id="sa2m11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> we found that it was not reduced in the low serum group (b = -0.105, 95% CI [-0.523, 0.348], P(b&gt;0) = 0.323, d = -0.096, 95% CI [-0.477, 0.317]), but was reduced in the high serum group (b = -0.492, 95% CI [-0.96, -0.033], P(b&gt;0) = 0.018, d = -0.45, 95% CI [-0.877, -0.03]), with a (non-significant) moderate effect size difference between the effects (b = -0.393, 95% CI [-0.918, 0.118], P(b&gt;0) = 0.066, d = -0.359, 95% CI [-0.838, 0.108]).</p><p>Lower values of <inline-formula><mml:math id="sa2m12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> imply more choice behaviour that the model cannot explain based on estimated values of the two spaceships. To see whether some of the increased variance can be explained by the tendency of participants to repeat actions or choices regardless of outcomes, we extended the M1 serum model to include a response stickiness (<inline-formula><mml:math id="sa2m13"><mml:mi id="b804ff11-145c-4d7f-bdff-b8b51da82864">ρ</mml:mi></mml:math></inline-formula>) and stimulus stickiness (<inline-formula><mml:math id="sa2m14"><mml:mi id="a4f5c78e-72bb-4050-aa30-80f014333f3b">π</mml:mi></mml:math></inline-formula>) parameter. We found some evidence that amisulpride in participants with high serum levels increased switching between responses, as indicated by the reduced <inline-formula><mml:math id="sa2m15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula> parameter (b = -0.466, 95% CI [-0.962, 0.043], P(b&gt;0) = 0.039). This effect was not present in the low serum group (b = -0.158, 95% CI [-0.618, 0.311], P(b&gt;0) = 0.251), with a non-significant difference between the effects (b = -0.294, 95% CI [-0.723, 0.13], P(b&gt;0) = 0.082). The inclusion of the two stickiness parameters, did not markedly change the posterior distributions of effects of amisulpride on <inline-formula><mml:math id="sa2m16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>η</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, but did reduce the effect on <inline-formula><mml:math id="sa2m17"><mml:mi id="e72c3e36-a45a-441f-a670-f75c7141158e">ω</mml:mi></mml:math></inline-formula> in the high serum group (b = 0.571, 95% CI [-0.361, 1.527], P(b&lt;0) = 0.111, see Figure 4 —figure supplement 2 for other relevant posterior distributions). We note however, that the model including stickiness parameters performed worse than the model without the stickiness parameters, with a lower out-of-sample trial-wise predictive performance (<inline-formula><mml:math id="sa2m18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mtext>Δelpd</mml:mtext></mml:mrow></mml:mstyle></mml:math></inline-formula>(sd)= -413 (31.5)).”</p><p>See also the discussion of these results (p.9 §1 and §2) that includes the following text:</p><p>“An important aspect of drugs that target D2 receptors is that they are known to mainly act on presynaptic D2 receptors at low doses, while binding to postsynaptic receptors prevailingly accounts for their effects at higher doses (Schoemaker et al., 1997). Presynaptic D2 receptors are believed to play an autoregulatory control of dopamine signalling through inhibition of synthesis and dopamine release (Ford, 2014). In our data, we find that the increase in model-based control did not scale with higher effective dose and was present in participants with either high or low serum levels in the blood. The effect in the high serum group was slightly reduced (and not robustly above zero, p = 0.111) in the computational model that included stickiness parameters, although we note that including stickiness parameters led to a poorer model fit. Taken together, this provides some evidence for the notion that the effects of amisulpride on model-based behaviour are not driven by postsynaptic effects but might rather be due to amisulpride increasing dopamine levels through presynaptic D2 receptor blockade and thereby boosting the willingness to apply cognitive effort.</p><p>Interestingly, amisulpride also increased choice stochasticity parametrised by the softmax inverse temperature parameter. In a paradigm with two choice options, it cannot be definitively determined whether this indicates higher decision-noise or increased exploration of alternative choices. We can however speculate that increased decision noise would lead to overall detrimental effects on learning in both trial types with same and different consecutive first stage states, which we do not observe in our data. The effect on the choice stochasticity parameter was only present in participants with a higher effective dose (Rosenzweig et al., 2002), suggesting that the effect was more likely to be post-synaptic. Similarly, in the same effective dose group, we found some evidence that amisulpride reduces response stickiness indicating increased switching between actions. This is well in line with a prominent model of the cortico-striatal circuitry implicating post-synaptic D2 receptors in exploration/exploitation (Frank, 2005) and supported by empirical data.”</p><disp-quote content-type="editor-comment"><p>2. According to supplementary Table 1, only the main effects of &quot;session&quot;, &quot;prev_state_diff&quot;, and &quot;prev_points&quot; were modelled as random slopes, whereas as fixed effects also all interaction terms were modelled. As it is generally recommended to maximize the random effects matrix in order to reduce the risk of false positives, I ask the authors to model also the interaction terms between these variables as random slopes. Does this change the observed amisulpride effects?</p></disp-quote><p>We thank the reviewer for this suggestion. We now use the model with the interactions in the manuscript, and the main findings have not changed. However, we note that the effect of amisulpride on trials where the first stage state was different (<inline-formula><mml:math id="sa2m19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>0.046 (95% CI [-0.007, 0.098], P(<inline-formula><mml:math id="sa2m20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>&lt;0) = 0.048) has slightly changed, and is now lower and has more uncertainty around it – i.e. a larger CI (<inline-formula><mml:math id="sa2m21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>0.036 (95% CI -0.091, 0.158], P(<inline-formula><mml:math id="sa2m22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>&lt;0) = 0.285). The interaction effect is still robust as is the effect of amisulpride on same first state trials. When comparing the random slopes from this model with computational parameters we see that the exploration parameter mostly explains choices in the same first state trials, while model-based weight explains the difference between the same and different first state trials (p.6 §1). We therefore interpret our findings as amisulpride having a general (likely a post-synaptic) effect on choice performance by increasing exploration, while still relatively boosting model-based relative to model-free behaviour.</p><disp-quote content-type="editor-comment"><p>3. Why did the authors control for BMI (supplementary Table 5)? If the intention was to control for the effective individual dose, body weight would be more relevant than BMI.</p></disp-quote><p>BMI was used in line with previous studies, but we agree with the reviewer that normalizing the weight by height makes less sense when considering effective doses. We now use weight in our analysis. Nothing changed though in our main conclusions, as neither weight nor BMI affects any of the inferences about the main outcome variables.</p><disp-quote content-type="editor-comment"><p>4. The inverse temperature parameter in the computational model is described as an indicator of both exploratory behavior and decision noise. Is exploratory behavior the same as decision noise in the current task, or does one parameter indeed measure two dissociable constructs?</p></disp-quote><p>Unfortunately, in this task the behavioural patterns arising from decision-noise and exploratory behaviour are not separable. We can only speculate that if amisulpride would increase decision noise, we would find a more generally detrimental effect on behaviour. It is therefore more likely that amisulpride increased choice switching due to higher drive for exploring other options.</p><p>This is now mentioned in the discussion (p.9 §2):</p><p>“Interestingly, amisulpride also increased choice stochasticity parametrised by the softmax inverse temperature parameter. In a paradigm with two choice options, it cannot be definitively determined whether this indicates higher decision-noise or increased exploration of alternative choices. We can however speculate that increased decision noise would lead to overall detrimental effects on learning in both trial types with same and different consecutive first stage states, which we do not observe in our data. The effect on the choice stochasticity parameter was only present in participants with a higher effective dose (Rosenzweig et al., 2002), suggesting that the effect was more likely to be post-synaptic. Similarly, in the same effective dose group, we found some evidence that amisulpride reduces response stickiness indicating increased switching between actions. This is well in line with a prominent model of the cortico-striatal circuitry implicating post-synaptic D2 receptors in exploration/exploitation (Frank, 2005) and supported by empirical data. In animal studies, activation of D2 receptors was shown to lead to choice perseverance and more deterministic behaviour, whereas D2 receptor inhibition increases the probability of performing competing actions and increases randomness in action selection (Sridharan, Prashanth, and Chakravarthy, 2006). In humans, a recent neurochemical imaging study showed that D2 receptor availability in the striatum correlated with choice uncertainty parameters across both reinforcement learning and active inference computational modelling frameworks (Adams et al., 2020). Increased choice uncertainty was also observed in a social and non-social learning tasks in a study using 800 mg of sulpiride, a dose that is known to exert post-synaptic effects (Eisenegger et al., 2014; Mikus et al., 2022).”</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Here are two small comments about the analyses. First, why didn't the authors include stickiness parameters in the model? This is very popular in our field because it allows us to capture variance in choice induced by preferences that are not related to maximizing reward. Second, the behavioral analysis that tests the effect of a previous reward on choice is not quite ideal, because it doesn't take into account that the same scalar reward (e.g., +1 point) can elicit a negative prediction error (if you expected +5) or a positive prediction error (if you expected -3). This issue can be remedied by computing prediction errors for the second-stage reward and then using their sign as a predictor of staying behavior.</p></disp-quote><p>We thank the reviewer for suggesting including the stickiness parameters. Although the results did not change much we do find some support for the fact that amisulpride increased switching between responses in individuals with high serum levels in the blood. This lends further support that higher doses of D2 antipsychotics might affect action selection policies. Regarding the reviewer’s second point, we agree that looking at the effects of previous points on staying behaviour is not ideal and might not account for cases where same reward sizes encourage or discourage choice repetition. This is exactly what motivates the computational modelling approach on top of using simple logistic regression to predict staying behaviour. We elaborate on this in the Results section on p.5:</p><p>“We note also that this analysis approach ignores one important aspect of the task, namely that subjects were comparing the relative points between two independently changing planets, thereby the points received in each trial should be seen in relation to the points that the participants expected to get were they to choose the other spaceship. To address these issues, we employed computational modelling.”</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>As suggested by reviewer #2, please repeat the analyses using continuous rather than categorical plasma levels (or justify the use of a categorical variable), and also include plasma levels for the model-free behavioral analyses.</p><p>Reviewer #2 (Recommendations for the authors):</p><p>The authors made a good job of revising the manuscript and successfully addressed almost all of my previous concerns. However, I still have some questions regarding the inclusion of plasma concentrations in the statistical analyses: First, I wondered why plasma concentrations were dichotomized into low versus high (and was this done based on the mean or the median)? It seems more straightforward to enter plasma concentrations as continuous predictors to the models, as this takes the full variation in plasma concentrations between individuals into account. Second, it seems that plasma concentrations were added only to the model-based computational analyses, but in order to be consistent the authors should do the same with their model-free behavioral analyses.</p></disp-quote><p>We thank the reviewer for pointing out the issue with plasma concentrations. We briefly explained in the Methods that the serum variable was dichotomized due to the skew in the distribution. Admittedly this was perhaps not spelled out clearly enough. We, thus, now mention this in the main text and describe the rationale in detail in the Procedure section of the Methods.</p><p>In results (p.6) we now say:</p><p>“We next looked at whether the effects of amisulpride were different based on the effective dose. We reran the parameter estimation including a variable for amisulpride blood serum levels as a group-level covariate in the hierarchical model (Figure 5). We used a categorical variable due to the highly skewed distribution of serum levels (DeCoster et al., 2011, see Methods for details).”</p><p>In the methods we elaborate on this on p.10:</p><p>“For 18 participants the value of amisulpride was at maximum (&gt;604 <inline-formula><mml:math id="sa2m23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>g/l), leading to a highly skewed distribution, with no variance in the upper 50% quantile. Because of this we dichotomized the data into a categorical variable, whereby the high serum group consisted of participants with serum levels above 604 <inline-formula><mml:math id="sa2m24"><mml:mi id="d937e2cd-7892-4e2e-8e8d-4dd416d0c805">μ</mml:mi></mml:math></inline-formula>g/l (n = 18) and the low serum group had levels between 212.6 <inline-formula><mml:math id="sa2m25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>g/l and 602.5 <inline-formula><mml:math id="sa2m26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>μ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>g/l (n = 14).”</p><p>We also include the behavioural (“model-free”) analysis with serum levels which we agree adds to the consistency of the manuscript. The following paragraph has been added to the Results section (p.):</p><p>”We also reran the behavioural analysis, predicting the likelihood to stay with the previous choice as before, but including the serum variable. In line with the results from the computational model, we found that amisulpride significantly increased the difference between the effects of previous points on staying behaviour in different vs. same first state trials both in the low serum group (<inline-formula><mml:math id="sa2m27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> = 0.235, 95% CI [0.047, 0.43], P(<inline-formula><mml:math id="sa2m28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>&lt;0) = 0.006), as well as in the high serum group, although to a lesser extent (<inline-formula><mml:math id="sa2m29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> = 0.143, 95% CI [-0.03, 0.323], P(<inline-formula><mml:math id="sa2m30"><mml:msub id="c17ed805-afa8-498e-81c7-727e1bb421bf"><mml:mi id="ee986701-bc71-4c4e-8964-f0a6b4330160">β</mml:mi><mml:mtext mathvariant="normal" id="cb29eca6-36f8-41a8-a486-868e4d74db17">logodds</mml:mtext></mml:msub></mml:math></inline-formula>&lt;0) = 0.054). Conversely, in the high serum group, amisulpride decreased the effect of previous points in the same first state trials (b = -0.172, 95% CI [-0.34, -0.002], P(<inline-formula><mml:math id="sa2m31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>&gt;0) = 0.024), mirroring the effect of the computational model. In the low serum group amisulpride also decreased the effect of previous points on staying behaviour in the first state trials (<inline-formula><mml:math id="sa2m32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> = -0.147, 95% CI [-0.34, 0.036], P(<inline-formula><mml:math id="sa2m33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mtext>logodds</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula>&gt;0) = 0.060). Note that, although the 95% CI contained values above 0, this represents a slight inconsistency to the results from the computational model, where the exploration parameter <inline-formula><mml:math id="sa2m34"><mml:mi id="ae6fc11b-991d-4cea-9480-c78b7cd5bb05">η</mml:mi></mml:math></inline-formula> was not reliably reduced in the low serum group.”</p></body></sub-article></article>